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Introduction 
 
1. Cancer  
 
Even though cancer research has led to many rapid advances in the last quarter 
century, malignant neoplasms are still one of the major causes of death worldwide1. 
Currently, one in 4 deaths in the United States and Europe is due to cancer. Every 
year, more than 550000 people die of cancer in the United States alone, 
corresponding to over 1500 per day. Almost half of all men and more than a third of 
all women will develop cancer during their lifetimes2.  
It has been established that cancer, the transformation of a normal somatic tissue 
into a malignant tumor, is the result of a multi-step process of consecutive genetic 
alterations which confer specific properties to the a priori normal cell. This process 
originates in the mutation of a single gene in a single cell which then gives rise to 
clonal waves of abnormal daughter cells3. Since there are many obstacles in the 
mammalian organism for such a cell to multiply endlessly, the descending premalign 
cells undergo a constant process of Darwinian selection as they face different 
selection barriers. Since the endogenous mutation rate would not suffice to generate 
enough genetic alterations within the human life-span, these cells must possess a 
certain genetic instability in order to overcome the selection obstacles (Figure 1). 
 
 
Figure 1: Selection barriers and 
genetic instability in tumorigenesis 
Normal, non-malignant cells harbor a 
low intrinsic genetic instability rate and 
thus succumb easily to selection 
barriers, which inhibit tumor formation 
(a). Tumor cells or pre-malignant cells 
show a certain instability, which results 
in a more and more heterogeneous cell-
mass and increases the chance for at 
least one of these cells to overcome the 
selection barriers (b). If genetic 
instability is too high, DNA damage 
quickly accumulates and leads to 
unviability of the cells (c)4. 
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The degree of this instability is crucial for the further progression of the altered tissue. 
If the instability rate is too high, accumulation of DNA damage rapidly leads to 
unviability of the cell and if the rate of genetic instability is too low, it cannot 
overcome the selection barriers it faces4. Many different sources of genetic instability 
have been identified. One of them is the alteration or inactivation of DNA mismatch 
repair5. This leads to microsatellite instability which in turn produces nucleotide 
mutation rates two to three orders of magnitude higher than normal6. Another form of 
instability occurs at the chromosomal level. This chromosomal instability, 
accompanied by changes in chromosome size and number, can be due to alterations 
in different tumor suppressor genes involved in DNA maintenance7. This leads to 
destabilization of the segregation machinery during mitosis and provokes further 
aneuploidy8.   
 
1.1. Physiological alterations in cancer cells 
 
Regardless of the mechanism of genetic instability acting in a tumor cell, the types of 
mutations which are necessary to acquire the properties needed for cancer 
progression are always the same, either dominant gain of function mutations of 
oncogenes or recessive loss of function mutations of tumor suppressor genes. 
Altogether, there are six major selection barriers that must be overcome and 
accordingly six necessary alterations in cell physiology which must be acquired 
(Figure 2)9. 
 
     
Figure 2: Acquired capabilities of 
cancer cells 
Cancer cells need to establish six 
major characteristics to allow tumor 
initiation and progression: Self-
sufficiency in growth signals, 
insensitivity to anti-growth signals, 
evasion of apoptosis, limitless 
replication, sustained angiogenesis 
and tissue invasion and metastasis9. 
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Somatic cells need mitogenic growth signals in order allow their proliferation. These 
signals are transmitted in a paracrine manner, from one cell type to another, via the 
secretion of soluble signaling molecules that bind specific transmembrane receptors 
on the target cell. Thus, in order to be able to proliferate, tumor cells must acquire 
self-sufficiency in growth factors, either by secreting their own or by up-regulating the 
expression of the respective cell surface receptors, thereby becoming hyper-
responsive to ambient levels of growth factors that would not trigger proliferation in 
normal cells. Also, alterations in the signaling cascade downstream of the ligand-
receptor binding are possible, such as constitutively active receptors or downstream 
signal transduction molecules11.  
In addition to the limited presence of growth factors, another signaling mechanism 
restricts uncontrolled proliferation in normal tissue, namely antigrowth signals. These 
restrictive signals act in the same way as the mitogenic signals, via membrane bound 
receptors. Antigrowth signals block proliferation either by temporarily forcing the 
target cells into a quiescent cell cycle state (G0) or through the induction of terminal 
postmitotic differentiation, which is permanent9. In cancer cells, the responsiveness 
to these antigrowth signals must be disrupted to allow proliferation. 
Another hurdle for cancer progression is the apoptotic machinery, present in most 
cell types throughout the body. It initiates a programmed cell-death through the 
release of cytochrome C from the mitochondria and subsequent activation of 
caspases which lead to chromosome degradation and cell membrane disruption. 
This program can be triggered by many physiological signals such as soluble death 
factors which again bind to cell surface receptors or the abrogation of cell-matrix and 
cell-cell adherence molecules which normally inhibit the induction of apoptosis. In 
addition, intracellular sensor proteins are capable of detecting DNA damage. They 
can either induce cell cycle arrest, which gives the cell more time to repair the 
damage or apoptosis, if the damage is too severe10. There is a constant balance 
between pro- and antiapoptotic signals which can lead the cell in either direction. In 
cancer cells, all of these signaling pathways can be altered. Death factor receptors, 
intracellular proapoptotic regulators that sense DNA damage as well as transmitters 
of antiapoptotic survival signals can be mutated, rendering the cancer cell resistant to 
apoptosis9. 
Except its dependency on environmental signals, proliferation of somatic cells is 
further restricted by an inherent, cell-autonomous program. Most normal human cells 
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have the capacity for 60-70 doublings (the Hayflick limit) after which they fall into a 
state of senescence12. Even if this limit is circumvented in the mutated cancer cell, 
another problem persists. Due to the shortening of telomeres (repetitive, noncoding 
sequences at the end of each chromosome) the DNA becomes increasingly unstable 
with every supplemental round of replication which ultimately leads to cell death. The 
enzyme telomerase contains the template for telomeres in the form of a short RNA 
molecule. Even though it is normally inactive in somatic cells, it can be reactivated in 
cancer cells13.  
In order to allow cell function and survival, oxygen and nutrients have to be supplied 
by the vasculature. Therefore, a tumor exceeding a certain size must develop the 
ability to recruit new vessels. Analogously to the self-sufficiency in growth factors, 
this can be achieved by upregulation of proangiogenic growth signals, the 
downregulation of angiogenic inhibitors or alterations of the intracellular signaling 
pathways involved14. 
The last step in cancer progression is the colonization of distant organs through the 
formation of metastases. 
 
1.2. Lung cancer 
 
Despite the continuous reduction of smoking prevalence since the late 1960s and 
numerous therapeutic advances, lung cancer is still by far the most common cause of 
cancer-related deaths in Europe and the United States, accounting for one fifth of all 
cancer deaths2,15. Close to 70 % of lung cancer patients show locally advanced or 
metastatic disease at the time of diagnosis16. The overall 5 year survival rate is 15 to 
17 %17. 
Malignant lung cancer is histologically classified into two major groups which account 
for over 95 % of all lung cancers, the small cell bronchus carcinoma (SCLC) and the 
non-small cell bronchus carcinoma (NSCLC). The latter one is further divided into 
three subtypes, the large cell carcinoma, the squamous cell carcinoma and the 
adenocarcinoma. 
Adenocarcinomas are the most commonly observed lung cancer subtype in Europe 
(40 % of all lung cancers) and their incidence has increased over the past years. It 
has its origin in glandular tissue. Squamous cell carcinomas are a little less frequent 
(25 % of all lung cancers). Large cell bronchus carcinomas account for 5 to 10 % of 
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lung cancers18, 19. The small cell bronchus carcinoma is less frequent than the 
NSCLC (about 17 % of all lung cancers) and has the worst prognosis among lung 
cancers19, 20, 21. 
 
2. Metastasis 
 
Metastasis, the foundation of distant colonies by cancer cells, moving out of the 
primary tumor mass, travelling through the vascular system of the body and finally 
reaching a new soil allowing them to grow again, is the cause for 90% of cancer 
deaths22.  
In addition to the abilities necessary for primary tumor initiation, the establishment of 
metastases from a well vascularized malignant tumor requires several new ones. As 
for the primary tumor, this can be attributed to a number of alterations in the genome, 
whose chronological order coincides with the overcoming of several selection 
barriers.  
The first step in this process is the destruction of the basement membrane, a non-
cellular network of collagen fibers, anchoring the epithelium to the tissue underneath 
through cell-matrix adhesion. In cancer, the basement membrane is a mechanical 
barrier to uncontrolled invasive growth of malignant cells. In order for the tumor to 
grow beyond this boundary and enter the bloodstream, the basement membrane 
needs to be broken down23. This is achieved by the secretion of extracellular 
proteases which have the ability to degrade the adjacent extracellular matrix24. They 
do not necessarily originate from the tumor itself, but can be secreted by cancer 
promoting tumor associated macrophages (TAMs)25. 
Concomitantly to the clearance of this physical obstacle, cancer cells which are in 
most cases epithelial in nature must acquire a mesenchymal phenotype with the 
ability to migrate and thus leave their primary growth site, either directly into the 
surrounding tissue or into a nearby vessel which carries them across the entire body. 
The latter process is called intravasation. Epithelial and mesenchymal cells differ in 
various functional and phenotypic characteristics. Epithelial cells grow as layers of 
cells that show complete cell-cell adhesion with their neighbors through a multitude of 
specialized membrane structures such as gap junctions, tight junctions, adherens 
junctions and desmosomes. Furthermore, they exhibit an apical-basolateral polarity 
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which manifests itself through the distribution of cell adhesion molecules, cell-cell 
junctions and the organization of the actin cytoskeleton. In contrast, mesenchymal 
cells have a fibroblastoid spindle-like morphology and do not form tight cell layers, 
touching their neighbors only focally, nor do they show the same apical-basolateral 
polarity. They are highly motile in culture. The process by which epithelial cells turn 
into mesenchymal cells is called epithelial to mesenchymal transition (EMT). It is 
triggered by a variety of growth factors and requires several mutations26. 
The question whether cancer cells which have managed to enter the circulation 
home for specific organs in order to establish metastases or are merely retained by 
physical barriers is not completely solved. It seems however that both mechanisms 
are significant. Capillaries are small (3 to 8 µm in diameter) compared to most cancer 
cells (50 µm in diameter)27. It has been shown that lung and liver capillaries can 
arrest circulating cancer cells very efficiently, purely by size restriction28.There is also 
evidence for specific adhesion of cancer cells to certain endothelia, depending on 
their activation state29. Nevertheless, it seems that the preference of certain cancers 
to colonize specific organs does depend on their ability to proliferate inside the 
respective tissue rather than a homing mechanism. Multiple molecular factors have 
been identified, which give the tumor cells specific growth advantages inside specific 
tissues30, 31. 
 
3. Vessel development 
 
3.1. Blood vessels 
 
Mammalian cells require oxygen and nutrients for their survival. Since oxygen has a 
diffusion limit of 100 to 200 µm, every organism which grows beyond this size must 
assure the supply of its tissues through a widely ramified system of blood vessels. In 
order to generate such a system, mammals have to form new vessels constantly 
during development by processes called vasculogenesis, the recruitment of 
endothelial progenitors which spontaneously form new blood vessels and 
angiogenesis, the sprouting of new vessels from preexisting ones and subsequent 
stabilization of these sprouts by mural cells32. Many of the mechanisms involved in 
the vascular development of the embryo can be recapitulated in the adult organism. 
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This process, called neoangiogenesis, occurs for example during repair and healing 
following tissue damage. In general, angiogenesis is regulated by a balance of pro- 
and antiangiogenic factors33. The disturbance of this balance in either direction is the 
cause for a wide variety of diseases, including among others cancer progression, 
psoriasis, arthritis, blindness, neurodegeneration, hypertension, pre-eclampsia, 
respiratory distress and osteoporosis14, 34. In the case of cancer, neoangiogenesis 
allows the tumor to grow beyond a critical size, where the limited availability of 
nutrients and oxygen would restrict its growth. In addition, blood vessels serve as a 
gateway into the body, permitting the entrance of tumor cells into the circulation and 
the subsequent colonization of distant organs and thus the formation of metastases. 
The hypothesis that tumors produce proangiogenic substances was proposed in 
196835. It has become clear since then, that during cancer progression, an 
“angiogenic switch” is turned on, as the balance between pro- and antiangiogenic 
factors is moved towards angiogenesis9, 14. Several physiological changes which 
occur during tumor growth can trigger this angoigenic switch. Among them are 
hypoxia, low pH, hypoglycemia, mechanical stress from proliferating cells, 
inflammatory response following invasion by immune cells and mutation of genes 
that control angiogenesis regulators36, 37. The molecular players involved are 
numerous but present research indicates that the most important ones are members 
of the vascular endothelial growth factor (VEGF) and angiopoietin (Ang) families38. 
 
3.2. Lymphatic vessels 
 
In addition to the supply of nutrients and oxygen, several other biological 
maintenance functions are necessary in mammalian tissues, which cannot be fully 
accomplished by a closed cardiovascular system. The open lymphatic system 
assures the control of intercellular fluid transport through the absorption of 
extravasated water from the venous system and thus maintains an appropriate 
plasma volume and prevents pressure build-up inside the tissue. Furthermore, it 
plays a crucial role for the immune system of the body by serving as a route of 
transportation for leukocytes39. It is established during embryogenesis by the 
formation of primordial lymphatic vesicles through the budding off from venous 
endothelial cells40. Even though their origin is the same, lymphatic endothelial cells 
(LEC) are distinct from blood vascular endothelial cells41, 42. Lymphatic vessels show 
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differences in structural and functional properties from those of blood vessels. They 
are thin walled, have little or no basement membrane and their inter-endothelial cell-
junctions are discontinuous, which increases their permeability. Furthermore, they 
have a higher lumen diameter, are less regular and can frequently be collapsed. In 
the absence of a pressure source such as the heart, they have to maintain the lymph 
flow by contractions of the smooth muscles around them and direct it through a 
system of valves43. As is the case with angiogenesis, lymphatic vessels can develop 
in response to damage and inflammatory signals in somatic tissues, after 
embryogenesis is accomplished. Lymphatic vessel development is also dependent 
on a specific growth factor environment, which encourages or inhibits lymphatic 
endothelial cell migration and vessel formation44. Again, the disturbance of this 
balance results in many diseases such as chronic inflammations (e.g.: psoriasis or 
rheumatoid arthritis), lymph edema and hypertension45, 46, 47, 48, 49. In many human 
cancers, it is well established that regional lymph node metastasis is the first step of 
tumor dissemination50, 51. It is currently unclear whether lymphatics can really 
promote further metastases formation in distant organs in analogy to blood vessels, 
by serving as a “launch pad”, but it is known that tumor cells can enter the lymphatic 
vasculature, either by invading preexisting lymph vessels or by inducing 
lymphangiogenesis through the secretion of lymphangiogenic factors45, 50, 52, 53. 
Compared to angiogenesis, the physiological causes for lymphangiogenesis in the 
lung cancer cancer context, as well as the underlying molecular networks are poorly 
studied but similar signaling pathways are involved, such as specific members of the 
VEGF and Ang/Tie systems54, 55. 
 
3.3. The VEGF system 
 
The vascular endothelial growth factor family is a group of multifunctional signaling 
molecules with several important biological activities during embryonic development 
as well as in somatic tissue homeostasis of specific organs56. The VEGF family 
consists of seven secreted glycoproteins, VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
VEGF-E, VEGF-F and placental growth factor (PlGF)57, 58, 59.VEGF-E and VEGF-F 
differ from the other, endogenous VEGFs in their origin. VEGF-E is virally encoded 
and VEGF-F is a component of snake venom60. VEGFs convey their biological 
function through the binding to their respective receptors VEGFR-1 (Flt-1), VEGFR-2 
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(KDR), VEGFR-3 (Flt4) and lastly the coreceptors Neuropilin NP-1 and NP-2. Binding 
of these receptors leads to modification of multitude of downstream targets and 
alteration of cell behavior in many ways (Figure 3).  
 
 
 
 
Structure and function of VEGF-A 
 
VEGF-A (also called VEGF) was first identified as a permeability factor secreted by 
tumor cell lines61. Soon after, it became evident that VEGF also displays the ability to 
stimulate endothelial cell proliferation and migration, acting as an angiogenic factor62. 
VEGF-A is a homodimeric 46 kDa glycoprotein. Its gene is located on chromosome 
6p21.3, spans approximately 14 kb and consists of eight exons. Alternative splicing 
yields seven isoforms (VEGF-A206, 189, 183, 165, 148, 145, 121), where the numeric value 
denotes the number of amino acids in the protein (Figure 4).  
 
Figure 3: The VEGF-family 
Receptors, ligands and downstream pathways.85 
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Figure 4: VEGF-A 
Gene structure of human VEGF-A (a). Known splice variants of VEGF-A (b). Protein structure of 
VEGF-A (c) adapted from 63. 
 
All isoforms possess the N-terminal signal sequence, the dimerization domain and 
the VEGFR-binding domain, which are encoded in exons 1-5. They do however differ 
in their ability to bind to the highly negatively charged glycosaminoglycan 
carbohydrate heparin and similar molecules, which is encoded in exon 6 and 7. 
Furthermore, they can be divided into two families which differ by their six C-terminal 
amino acids, due to the existence of two alternative splice sites in exon 8, a proximal 
and a distal one (PSS and DSS). If the PSS is chosen, the resulting protein has pro-
angiogenic properties (VEGFxxx), if the DSS is selected, the protein exhibits anti-
angiogenic properties (VEGFxxxb)63. 
VEGF-A acts through the binding to its receptors VEGFR-1 (Flt-1) and VEGFR-2 
(Flk-1). These are transmembrane tyrosine kinases, specifically expressed on 
vascular endothelial cells. Upon binding, they dimerize and autophosphorylate their 
intracellular kinase portion, leading to the activation of multiple downstream 
effectors64. In addition, VEGF-A also interacts with the neuropilin receptors (NP-1 
and NP-2), which are expressed on vascular endothelial cells and neurons. 
In embryonic development, VEGF-A expression coincides with blood vessel 
formation65. Its mRNA can be identified in the primary vasculature, the primordial 
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heart, kidney and brain66. The ablation of even a single allele results in embryonic 
lethality due to abnormal vascular development67.After birth, as the endothelial 
development slows down, VEGF-A expression declines accordingly to low levels. 
Nevertheless, VEGF-A expression is persistent in some specific somatic tissues such 
as kidney, brain, placental, lung and cardiac endothelia in order to maintain a 
specialized, fenestrated endothelium68, 69, 70, 71, 72. The effects of specific over-
expression of VEGF-A in defined tissues further underline its importance as a major 
regulator of blood vessel development and maintenance in embryogenesis and in the 
adult organism73. 
Also, VEGF-A plays a significant role in wound healing which is impaired in mice 
carrying a VEGF-A mutation74.Eventhough VEGF-A165 is the predominant isoform in 
most tissues, VEGF-A189 is highly expressed in the rat heart and lung and VEGF-A121 
is the most abundant isoform in the placenta58, 75, 76. 
 
In addition to its ability to induce proliferation, migration and tube formation of 
endothelial cells, VEGF-A can also provoke the attraction of hematopoietic stem cells 
and monocytes as well as osteoblast-mediated bone formation57, 77. 
Apart from its important physiological roles in organogenesis, vessel maintenance 
and tissue repair, aberrant VEGF-A expression has a strong influence on tumor 
growth and progression. The over-expression of VEGF-A165 and VEGF-A189 has 
been shown to be involved in the vascularization of various cancers, including 
bronchus carcinoma75, 78. 
VEGF-A expression can be induced in vitro by a multitude of other growth factors 
such as platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), 
epidermal growth factor (EGF) and transforming growth factor beta (TGF-β). 
Another prominent feature of VEGF-A regulation is its inducibility by hypoxia through 
the HIF-1 alpha pathway. So far, it is the only angiogenic factor for which this has 
been shown both in vivo and in vitro79. 
In conformity with this, VEGF-A expression in the tumoral context can originate from 
the tumor itself as a response to hypoxia. Nevertheless, VEGF-A production can also 
occur as a consequence of inducing factors secreted by stromal cells. Most leukocyte 
subtypes produce PDGF, bFGF, EGF and TGF-β, as well as VEGF-A itself, therefore 
stimulating VEGF-A expression and angiogenesis inside the tumor and the adjacent 
20 
 
tissue80, 81. Especially important in this respect are tumor associated macrophages, 
which are attracted by tumor secreted colony stimulating factor 1 (CSF-1)82. 
VEGF-A promotes cancer not only by its ability to stimulate angiogenesis, but also by 
the inhibition of the functional maturation of dendritic cells, thereby attenuating the 
anti-tumoral immune response83, 84. 
 
Structure and function of VEGF-C and VEGF-D 
 
VEGF-C was first discovered in 1996, when it was cloned from a cDNA library of 
human prostate cancer cells. It was found during the search for a ligand for VEGFR-3 
(Flt4). Since it was known that Flt4 is specifically expressed on lymphatic endothelia, 
it was soon clear that VEGF-C plays a role in the regulation of lymphangiogenesis86.  
The active form of VEGF-C is a 21 kDa glycoprotein. Its gene is located on 
chromosome 4q34, spans over 40 kb and comprises 7 exons. In contrast to VEGF-A, 
where different isoforms are the result of alternative splicing, VEGF-C is produced as 
a single precursor protein, which is proteolytically processed by the intracellular 
secretory proprotein convertases furin, PC5 and PC787, 88. VEGF-C is then secreted 
as a VEGFR-3 binding form, containing two 31 and 29 kD subunits, linked together 
by disilfude bonds. The factor is further proteolyzed in the extracellular environment, 
leading to the final 21 kD homodimeric protein, with high affinity for both VEGFR-2 
and VEGFR-389. VEGF-C possesses a VEGF homology domain, which shows 31 
and 61 % protein sequence identity to VEGF-A and VEGF-D respectively. 
As VEGFR-2, mentioned earlier already, VEGFR-3 is a receptor tyrosine kinase 
which gets activated upon binding, leading to the subsequent phosphorylation of a 
multitude of downstream effectors90. In contrast to VEGFR-2, VEGFR-3 expression in 
the adult organism is mostly confined to lymphatic endothelia91, 92. Furthermore, 
VEGF-C has the ability to bind the neuropilin-2 receptor, which is internalized with 
VEGFR-3 upon stimulation and may increase affinity of VEGFR-3 for VEGF-C93. 
In embryogenesis, VEGF-C expression is found predominantly at sites of lymphatic 
development51, 94. In mice, where VEGF-C has been deactivated, lymphatic 
endothelial cells begin differentiation but fail to migrate from the veins to form primary 
lymph sacs94, 95, 96. In addition, homozygous deletion of VEGF-C in mice causes 
lethality through a complete absence of the lymphatic system. Even heterozygous 
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deletion leads to severe lymphatic hypoplasia94. This suggests that VEGF-C has a 
predominant role in lymphangiogenesis and the establishment of a lymphatic system. 
VEGF-C also plays a role in angiogenesis, since it binds VEGFR-2 and has the 
ability to induce mitogenesis, migration and survival of endothelial cells41. Its 
angiogenic function is however not essential for blood vessel development.  
VEGF-C has been shown not only to be involved in lymph vessel development during 
embryogenesis, but also in the context of inflammation and tissue repair, which was 
proven in a rabbit cornea model of inflammatory lymphangiogenesis. Marcophages 
have been found to abundantly express VEGF-C and lymphangiogenic responses 
are inhibited upon macrophage depletion97. In addition, VEGF-C mRNA expression is 
induced in ECs in reponse to proinflammatory cytokines suggesting that these can 
play a role in VEGF-C mediated lymphangiogenesis97, 98.  
VEGF-C is linked to a number of diseases. It has been shown that abundant VEGF-C 
expression leads to excessive lymphangiogenesis and rejection in human kidney 
transplants99. In addition, high VEGF-C expression is found in arthritic joint synovium 
of patients suffering from rheumatoid arthritis, indicating that lymphangiogenic 
response is insufficient in this disorder100.  
Importantly, VEGF-C shows a possible influence on cancer progression, including 
lung cancer. It was found to promote lymphangiogenesis in human lung 
adenocarcinoma as well as increased lymph node metastasis in lung 
adenocarcinoma and non-small cell lung cancer90, 101. Although enlarged extra-
tumoral lymphatic vessels have been found, functional intra-tumoral lymphatic 
vessels have not102.  
Similarly to VEGF-A, VEGF-C is upregulated by a variety of inflammatory cytokines, 
such as insulin-like growth factor-1 (IGF-1), platelet derived growth factor (PDGF), 
epidermal growth factor (EGF), transforming growth factor beta (TGF-β) and basic 
fibroblast growth factor (bFGF). 
In contrast to VEGF-A, VEGF-C is not upregulated by hypoxia103, 104. 
 
Murine VEGF-D was found by differential mRNA screening of mouse fibroblasts, 
whereas in humans, it was identified by computer-based homology searching for 
VEGF-related sequences105, 106. 
The VEGF-D gene is located on chromosome Xp22 and spans about 50 kb. It shows 
similar organization to VEGF-C, with 7 exons and 6 introns90. The active form of 
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VEGF-D is also a 21 kDa glycoprotein and its origin is very similar to VEGF-C. It gets 
translated as a 50 kDa preprotein, which is further proteolytically processed by the 
same proprotein convertases, as VEGF-C (PC5 and PC7)107. This results in the 
active, homodimeric 21 kDa form. It also possesses the VEGF homology domain, 
which shows 30 % sequence identity to VEGF-A and 61 % identity to VEGF-C90. 
Overall, it is 48 % identical to VEGF-C. As VEGF-C, human VEGF-D has the ability 
to bind and activate VEGFR-2 and VEGFR-3, as well as NP-2, although with different 
binding affinities. Interestingly, murine VEGF-D only binds VEGFR-3, suggesting a 
different role in mice108.  
During embryogenesis, VEGF-D expression can be detected in many tissues, most 
abundantly in the lung and skin109. In contrast to VEGF-C, deletion of VEGF-D does 
not affect the development of lymphatic vasculature94, 110.  
Nevertheless, VEGF-D has the same mitogenic, migration and survival effect on ECs 
as does VEGF-C89. In addition, it presents prolymphangiogenic features in the same 
context as VEGF-C, namely during inflammatory response and wound healing, 
where it is also expressed by macrophages97. 
Concerning cancer, VEGF-D shows similar tendencies as VEGF-C, although it is far 
less intensively studied. It has been shown to increase lymphangiogenesis and 
metastasis to the lymph nodes in experimental tumor models and it seems to 
enhance angiogenesis as well111, 112. In the case of lung cancer, very few 
investigations have been conducted to this date, but it has recently been suggested 
that VEGF-D, along with VEGF-C may be involved in lymphatic metastasis in 
experimental intrathoracic lung cancer113. Also, it has a prognostic value in general 
for lymphatic vessel invasion and survival in certain human cancers114. 
Regulation of VEGF-D is quite different from VEGF-C since it is not upregulated in 
the presence of inflammatory cytokines. There are indications that VEGF-D may be 
inducible by hypoxia, as its genomic sequence reveals a hypoxia response element 
and VEGF-D has been shown to be upregulated by hypoxia in rat lung smooth 
muscle cells115. Also, it is induced by the activation of the proto-oncogene c-fos and 
by cell-cell contact, mediated by cadherin-11116 ,117. 
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3.4. Tumor associated macrophages and CSF-1 
 
Since the nineteenth century, it has been known that macrophages are present within 
and around tumors118. For a long time, it has been widely accepted that these tumor-
associated macrophages (TAMs) exert a tumor suppressive role, by performing their 
usual immunological and repair functions, such as the recruitment and activation of 
other immune cells or the production of proteases in order to eradicate the tumor119. 
Nevertheless, evidence has grown recently that TAMs may play a less appreciated 
role during tumor progression. Instead of activating other immune cells, TAMs may 
even inhibit their action by secretion of TGF-β, a cytokine which attenuates immune 
response120. In addition, they are also capable of secreting several matrix 
metalloproteinases, which can degrade extracellular matrix and the basement 
membrane which serves as a barrier against invasive tumor growth121. Most 
importantly, TAMs can strongly promote angiogenesis and lymphangiogenesis 
through the secretion of bFGF, angiopoietins, tumor necrosis factor-α (TNF-α), 
interleukin 1 and 8, thymidine phosphorylase and also VEGF-A, VEGF-C and VEGF-
D33, 121. In addition, VEGF-A serves as a chemoattractant for macrophages and 
further increases the invasion by TAMs (Figure 4).  
Colony stimulating factor-1 (CSF-1) is the most potent attractant for macrophages119. 
Its gene was discovered in 1985 in a genomic library122. The gene is located on 
chromosome 1p21, consists of 10 exons and spans about 20 kb.  
There are two forms of alternative splicing of the CSF-1 mRNA. One implies the 
alternative use of exon 9 or 10, which encode the 3’ untranslated region. The other 
leads to alternative splicing in exon 6 of which a large part can be left out, resulting in 
two different forms of the CSF-1 precursor. The form containing full-length exon 6 
encodes a protein which is then glycosylated and cleaved either at the N or C-
terminal end. It is secreted respectively either as a glycoprotein or a proteoglycan of 
86 kDa. The shorter precursor which lacks part of exon 6 is expressed as a 
membrane-spanning glycoprotein, which is only released by slow proteolysis. The 
existence of a membrane-bound as well as a secreted form of CSF-1 suggests two 
mechanisms of action, one of which is mediated by direct cell-cell contact, the other 
one is a response to the environmental concentration of secreted CSF-1.  
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CSF-1 exerts its biological functions by binding to its receptor CSF-1R, strongly 
expressed on the surface of macrophages. It is a membrane-bound tyrosine kinase 
and, upon binding, phosphorylates a multitude of target molecules123.  
CSF-1 has the ability to promote macrophage survival, proliferation, differentiation 
and chemotaxis. It has been shown to be overexpressed in many human cancers, 
including ovarian, uterine, breast and prostate tumors. Importantly, CSF-1 has the 
ability to induce VEGF-A expression124, 125, 126, 127. 
 
 
 
4. ANGPTL4 
  
Angiopoietin like-4 (ANGPTL4) was discovered in 2000 by multiple groups 
independently, during a search for additional angiopoietin-related proteins from 
embryonic cDNA, as a fasting-induced gene or as a factor expressed during 
preadipocyte differentiation128, 129, 130. 
ANGPTL4 is a 43 kDa glycoprotein. Its gene is located on chromosome 19p13, 
spans approximately 7 kb and consists of seven exons129. Two isoforms are 
produced via alternative splicing, the shorter one lacking exon 4 and it is unknown in 
Figure 4: Pro-tumorigenic 
functions of TAMs 
Tumor associated macrophages 
(TAMs) can be attracted to tumors 
by hypoxia or recruited by tumor-
released factors such as CSF-1. 
They secrete angiogenic factors, as 
well as proteases which facilitate 
tumor invasion119. 
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what respect this alters its function. The ANGPTL4 protein possesses two structural 
domains, an N-Terminal coiled-coil domain and a C-terminal fibrinogen-like domain. 
It shows oligomerization, mediated by disulfide bonds, prior to secretion and can be 
proteolytically processed by a membrane-associated protease, leading to the release 
of the full length form, and a truncated form, consisting of the N-terminal coiled-coil 
domain131. The latter can form higher oligomers after secretion132. 
The ANGPTL family of proteins is named for its structural resemblance to 
angiopoietins. These are pro-angiogenic proteins which bind the receptor tyrosine 
kinases Tie 1 or Tie 2 but unlike angiopoietins, ANGPTLs do not bind either of these 
receptors and are considered orphan ligands133.  
ANGPTL4 is expressed predominantly in adipose tissue, liver and placenta, but also 
keratinocytes, intestine and pituitary gland134.  
In general, ANGPTL4 is best known for its ability to inhibit lipoprotein lipase (LPL), a 
membrane-associated enzyme found on endothelial cells and responsible for the 
hydrolysis of triglycerides in plasma lipoproteins, thereby generating fatty acids for 
storage or energy production. This inhibition is accomplished by the selective binding 
of LPL and its subsequent conversion from active dimers to inactive monomers132.  
It has been suggested that, in conformity with its name giver, ANGPTL4 may have 
pro-angiogenic effects, since its expression is strongly increased in human fetal 
cardiac cells and neonatal rat cardiomyocytes, when cultured under hypoxia135. 
However, ANGPTL4 expression has been shown to be activated by hypoxia 
inducible factor-1α in many tissues, not only cardiac cells and in other studies, 
ANGPTL4 has even been shown to inhibit angiogenesis134, 136. Also, ANGPTL4 
seems to enhance cell survival and modulate cell-cell adhesion of endothelial cells128, 
137.  
Concerning cancer, systemic ANGPTL4 overexpression in transgenic mice has been 
shown to inhibit metastasis by xenografted melanoma cells138. 
Most interestingly and in contrast to previous findings, xenografted breast carcinoma 
cells overexpressing ANGPTL4 seem to have strongly increased metastatic potential, 
specifically to the lungs139. This ability is attributed to an endothelium-disruptive effect 
of ANGPTL4, which is in conformity with other recent publications, where ANGPTL4 
has been shown to loosen endothelial cell-cell adhesion137.  
The pathways of ANGPTL4 regulation are still largely unknown. It seems to be 
upregulated by fasting, hypoxia and by TGF-β134, 139. 
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Rationale 
 
The cell lines used in this thesis included NSCLC (H460 large bronchus carcinoma, 
H520 squamous bronchus carcinoma, Calu-3 bronchus adenocarcinoma) as well as 
SCLC cells (DMS 53 small cell bronchus carcinoma).  
The main aim was to develop murine xenograft models of all four major bronchus 
carcinoma subtypes and to assess differences in their growth, neoangiogenesis, 
lymphangiogenesis and metastases formation. 
In addition, the question was addressed whether these phenotypic differences 
correlate with the mRNA or protein expression levels of certain known angiogenic 
and lymphangiogenic factors in vitro as well as in vivo, namely members of the 
vascular endothelial growth factor family (VEGF-A, VEGF-C and VEGF-D), the 
colony stimulating factor-1 (CSF-1) and the novel angiopoietin-related molecule 
angiopoietin like-4 (ANGPTL4). 
This may allow the analysis of advantages and disadvantages of antiangiogenic 
therapies, as well as the development of new experimental approaches in different 
forms of lung cancer.  
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Materials and Methods 
 
1. Cells 
 
1.1. Cell lines 
 
H460 (ATCC number HTB-177)  
H460 is an epithelial-like metastatic human large cell bronchus carcinoma cell line, 
isolated in 1982 from the pleural fluid of a male patient. The cell line does form 
tumors in nude mice and grows in culture in adherent monolayers with an average 
doubling time of 23 hours in medium supplemented with 10% fetal bovine serum 
(FBS). It is hypotriploid with a modal chromosome number of 57 and several 
structural abnormalities, such as the absence of several normal chromosomes. The 
cells show p53 expression comparable to normal lung tissue. 
 
H520 (ATCC number HTB-182)  
H520 is an epithelial-like human squamous cell bronchus carcinoma cell line, isolated 
in 1982 from a sample of the lung mass taken from a male patient. It forms tumors in 
nude mice and grows in culture in adherent monolayers with an average doubling 
time of 61 hours in medium supplemented with 10% FBS. It is hypotriploid, with an 
average chromosome number of 58 and many structural abnormalities, such as the 
absence of several normal chromosomes. The y chromosome can no longer be 
detected and the X is single. The cells show greatly reduced p53 expression in 
comparison with normal lung tissue.  
 
Calu-3 (ATCC number HTB-55)  
Calu-3 is an epithelial-like metastatic human bronchus adenocarcinoma cell line, 
isolated from the pleural fluid of a male patient. It forms well differentiated 
adenocarcinomas in nude mice and grows in culture in adherent monolayers. It is 
hypotriploid with some structural abnormalities, including the absence of several 
normal chromosomes. The Y chromosome can no longer be detected. 
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DMS53 (ATCC number CRL-2062)  
DMS53 is an epithelial-like human small bronchus carcinoma cell line, isolated in 
1975 from a mediastinal biopsy of a male patient. It is tumorigenic in nude mice and 
grows in culture in adherent monolayers. It secretes a large variety of hormones. 
 
1.2. Cell culture 
 
The aim of cell culture is to sustain cell proliferation in an artificial environment by the 
adjustment of several factors, such as growth media composition, pH and 
temperature, mimicking their original environment.   
H460 cells were cultured on 10 cm tissue culture dishes (Iwaki) in 15 mL RPMI 
medium, supplemented with 10% FBS and penicillin/streptomycin (pen/strep, PAA) in 
order to suppress the growth of unwanted microorganisms. The medium was 
changed twice a week and incubation took place in an incubator (Binder) at 37°C and 
5% CO2. Subcultivation was conducted at 80% confluency and the cells were split at 
a 1:8 ratio.  
H520 cells were cultured under the same conditions. 
Calu-3 cells were cultured in MEM medium, supplemented with 10% FBS and 
pen/strep. Sodium pyruvate and non-essential amino acids (NEAA) were added as a 
supplement. Medium changes and subcultivation were conducted in the same way 
as for the other cell lines, but the cells were split at a ratio of 1:6. 
DMS53 cells were cultured in Waymouth’s medium, supplemented with 10% FBS 
and pen/strep. Medium changes were also conducted twice a week but the cells 
were split at a lower confluency of 60% and at a lower ratio of 1:3. 
Subculturing of the cells 
 
Since many cells show growth inhibition and can become necrotic when in close 
contact, they must be split at a defined confluency. This is achieved by digestion of 
cell-cell junctions by trypsin, a protease found in the digestive tract of many 
vertebrates. 
 
Cell culture media and phosphate buffered saline (PBS) were pre-warmed in a 37°C 
water bath. The exhausted medium was removed from the culture dishes by pipetting 
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and the cells were washed twice with PBS. 1 mL 1x Trypsin-EDTA was added to the 
cells and the plates were placed in the incubator (37°C) for 10 minutes. A 50 mL 
centrifuge tube was filled with 10 mL culture medium and the detached cells were 
harvested and transferred from the plate to the tube. The cells were pelleted by 
centrifugation (Heraeus Labofuge 400R) at 500 x g for 3 minutes. The supernatant 
was discarded and the cells were resuspended in 1 mL culture medium. New petri 
dishes were inoculated with the volume corresponding to the respective split ratio 
and placed in the incubator (37°C, 5% CO2).  
 
1.3. Cell counting 
 
For subsequent experiments, the cells were counted using a hemocytometer 
(Neubauer cell counting chamber), which is a graduated counting chamber that can 
be viewed under a microscope to determine the concentration of cells in a 
suspension.  
The instrument is made of ground glass with a central area that is defined by a set of 
grooves that form an “H” shape. Two counting areas with ruled grids are separated 
by the horizontal groove of the H. A glass coverslip is held at 0,1 mm above the 
surface of the counting areas by ground glass ridges on either side of the vertical 
grooves of the H shape. Each side (counting area) of a hemocytometer is etched with 
a grid of 9 square millimeters which is further subdivided into mm2. Since each mm2 
has a depth of 0,1 mm, the corresponding volume is 0,0001 mL. By multiplying the 
obtained cell count by the dilution factor and 104, the cell number per mL in the 
original suspension can be determined. 
Cell counting was conducted as follows: 
The cells were trypsinized and collected as for subcultivation and resuspended in 1 
mL culture medium. 10 µL of this suspension were diluted in 990 µL PBS in an 
eppendorf tube, resulting in a dilution factor of 1:100. In order to distinguish dead 
cells, 100 µL of this dilution were mixed with 100 µL trypan blue (Sigma) on a 
separate glass slide. Trypan blue is a live dye which selectively traverses the cell 
membrane of dead cells only. The counting chamber and glass cover slip were 
cleaned with 70% ethanol and the slip was placed on the chamber. The diluted cell 
suspension was pipetted onto the border of the glass cover slip and sucked into the 
counting chamber by capillary action. Live cells were counted in the four outer 1 mm2 
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squares of both counting areas and the result was averaged and multiplied by 2 x 
100 x 104 = 2 x 106 to obtain the cell concentration [cells/mL] of the initial suspension.  
 
1.4. DiI labeling of cells 
 
DiI (1,1'-dioctadecyl-3,3,3'3'-tetramethylindocarbocyanine iodide) is a non-toxic 
hydrophobic and lipophilic cyanine dye, which is retained in lipid bilayers and diffuses 
laterally to stain the entire cell. It exhibits an absorption maximum at 549 nm and 
emission at 565 nm. Its fluorescence is significantly enhanced upon membrane 
incorporation.  
Several different cell types were labeled, the tumor cell lines (H460, H520, Calu-3 
and DMS53) before injection into mice as well as lymphatic endothelial cells (LEC), 
which were used for the assessment of tube formation, as described later. 
 
The staining procedure was conducted as follows: 
2 µL of DiI stock solution (Invitrogen) were added to 2 mL of cell suspension in PBS 
in a 15 mL centrifuge tube and mixed by inverting. The mixture was incubated for 10 
min at 37°C, followed by 5 min on ice. The cells were spun down at 500 x g for 3 
minutes and washed with 10 mL PBS. This procedure was repeated 3 times to a total 
of 4 washes. The cells were resuspended in 1 mL culture medium for the tube 
formation assay or ringer solution for the injection into mice. 
 
2. Xenografts 
 
2.1. Establishment of tumor growth 
 
The mouse is the most common model organism in cancer research. The murine and 
human genomes have approximately the same size, contain the same number of 
genes and show extensive synteny (conserved gene order). Most human genes have 
mouse counterparts and their functions are closely related.  
Mice are small, easy to maintain in the laboratory (compared to most mammals) and 
have a short breeding cycle of about 2 months. Many mutants are available. Human 
tumor cell lines can give rise to progressively growing, and potentially lethal cancers 
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in mutant, immune-deficient mice which allows the use of human tumor xenografts 
for the study of virtually all types of anti-cancer drugs and treatment strategies. 
Obvious disadvantages of xenograft models are that the tumor cells and target organ 
are not from the same species and that the study of initiating events in 
carcinogenesis is precluded. Nevertheless, these models appear to have 
considerable utility for the investigation of diverse human cancers. 
 
Male nude mice (Athymic Nude-nu) were obtained from a commercial source (Harlan 
Winkelmann GmbH, Borchen, Germany) and housed under sterile conditions at the 
Department of Biomedical Research at the Medical University of Vienna. The mice 
were acclimatized for 2 weeks after arrival. 100 µL of tumor cell suspension in Ringer 
solution were injected subcutaneously through a 27-gauge needle into the left flank.  
For the assessment of tumor growth, two randomized groups of 4 animals were 
established for each of the 4 cell lines to a total of 32 animals. Each group received a 
different number of cells (5 x 106 or 10 x 106), chosen according to past publications 
(Table 1). Two animals of each cell-number group were injected with unmodified 
cells, while the remaining two animals received DiI-labeled cells in order to trace 
possible tissue invasion and distant metastases formation.  
 
Cell line Nr. of animals Cell number 
H460 4 5 x 106 
 4 10 x 106 
H520 4 5 x 106 
 4 10 x 106 
Calu-3 4 5 x 106 
 4 10 x 106 
DMS53 4 5 x 106 
 4 10 x 106 
  
        Table 1: Animal groups for xenograft model establishment 
  
 
Tumor size was measured with a caliper every 2 to 3 days after implantation of the 
cells. Caliper measurements were used to calculate tumor volumes using the formula 
V = π / 6 * (length * width * width) and to generate growth curves. As soon as the 
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tumor size exceeded 2 cm3, the animals were killed by intra-peritoneal injection of 
Ketavet (200 mg/kg) and Rompun (10 mg/kg).  
The tumors were removed, weighed and halved. One part of the tumor mass was 
fixed in formalin, the other one was frozen in liquid nitrogen for further analysis. In the 
case of the DiI-labeled cells, tumors, as well as defined organs (lung, lymph nodes, 
liver, kidney, and brain) were extracted in a sterile environment, under a tissue 
culture hood according to the cell isolation procedure described later. The unlabeled 
tumors were also subjected to cell isolation and prepared for flow cytometric analysis 
as described later. 
 
2.2. Cell isolation 
 
Surgical instruments were sterilized by autoclaving. 5 mL of PBS were added to 10 
cm petri dishes and a sterile 100 µm nylon mesh cell strainer (BD Falcon) was placed 
in each dish. After sacrification, the mice were placed in a tissue culture hood and 
their skin was doused with 70% ethanol. Using surgical scissors, an incision of about 
2,5 cm in length was made in the abdomen on the left side of each animal (at the 
tumor site), cutting the skin but not the peritoneal wall. With a fresh pair of surgical 
scissors, the tumor was extracted, weighed and divided into three parts. One part 
was placed in the cell strainer for cell isolation, the other two were fixed in 
formaldehyde or frozen in liquid nitrogen. With another fresh pair of surgical scissors, 
the peritoneal wall was cut and lung, discernible lymph nodes, liver, kidney and brain 
were extracted, using new and sterilized forceps and scissors for every organ. The 
organs were placed into a new cell strainer. The extracted tumors and organs were 
cut into small pieces with sterilized scissors and meshed through the cell strainer by 
gently applying force using the Gilson pipettor and the rubber end of a plunger from a 
5 mL syringe. The resulting suspension was filtered again through a new cell strainer, 
transferred into a 50 mL tube and centrifuged at 500 x g for 3 minutes. The pellet was 
resuspended in 1 mL culture medium and the cells were seeded onto a new 10 cm 
petri dish, supplied with 15 mL culture medium. 
Tumor cells were isolated in this way for every animal, whereas organ cells were only 
isolated from animals bearing DiI-stained tumors, in order to identify metastatic cells 
in subsequent cell culture.  
When colony formation and extensive growth of cells isolated from an organ was 
33 
 
observed, cells were picked, further subcultivated and their human provenance was 
checked by PCR. 
 
2.3. Flow cytometric analysis 
 
Flow cytometry is a technology that simultaneously measures and then analyzes 
multiple physical characteristics of single cells, as they flow in a fluid stream through 
a beam of light. The properties measured include relative size and relative granularity 
and they are determined using an optical-to-electronic coupling system that records 
how the cell scatters incident laser light and emits fluorescence.  The cells can be 
additionally labeled with a range of fluorescent dyes which can be coupled to specific 
antibodies.  
 
CD31, also named platelet endothelial cell adhesion molecule-1 (PECAM-1), is a 
molecule present on the surface of all endothelial cells, but also platelets, 
macrophages, T cells and neutrophils. It plays a role in the successful identification 
and subsequent degradation of damaged neutrophils by macrophages through the 
reciprocative binding of CD-31 molecules of both cells. Since it is ubiquitously 
expressed on all endothelial cells, it can be used in combination with other markers 
to identify specific endothelial cells, such as LECs. 
Lymphatic vessel endothelial hyaluronan receptor (LYVE-1) is a protein involved in 
the binding of hyaluronic acid by lymphatic endothelial cells. Since it is exclusively 
expressed on LECs, it can be used as a specific marker. 
 
In order to determine the incidence of murine lymphatic endothelial cells (LECs) in 
xenografted tumors and thus assess the degree of intra-tumoral lymphangiogenesis, 
isolated cells were double-stained with two antibodies against the lymph-specific cell-
surface proteins CD31 and LYVE-1.  
The previously unlabeled LYVE-1 (MBL) antibody was detected by a secondary 
antibody (Jackson), labeled with fluorescein isothiocyanate (FITC), which shows 
excitation at 494 nm and emission at 521 nm 
The CD31 antibody (BD Pharmingen) was directly labeled with phycoerythrin (PE), 
which has an absorption peak at 495 and an emission peak at 575 nm.  
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7-Amino-actinomycin D (7aad) (BD Pharmingen) was used to discriminate dead 
cells. It has an excitation maximum at 546 and shows emission at 647 nm. 7aad has 
a strong affinity for DNA but is unable to pass through intact cell membranes, thus 
staining only dead cells. 
 
The preparation and labeling of isolated cells was conducted as follows: 
After extraction and isolation, tumor cells were resuspended in 1 mL erythrocyte lysis 
buffer and incubated for 8 min at 4°C. 40 mL PBS were added and the tube was 
centrifuged at 500 x g for 3 minutes. The cells were resuspended in 1 mL PBS and 
counted. 106 cells were transferred to a flow cytometry tube and brought to a volume 
of 1 mL with PBS, as a control. 2,5 x 105 cells were transferred to another flow 
cytometry tube and brought to a volume of 0,5 mL with PBS. 2,5 µL of unlabeled rat 
anti-mouse LYVE-1 antibody were added to a dilution of 1:200 and the mixture was 
incubated for 30 min at 4°C. The cells were spun down at 500 x g for 3 minutes, the 
supernatant was discarded and the cells were washed in 4 mL PBS, which was 
removed after another centrifugation. Again, the cells were resuspended in 500 µL 
PBS and 12,5 µL FITC-conjugated anti-rat antibody was added to a dilution of 1:40. 
The cells were incubated for 30 min at 4°C, washed and resuspended as previously. 
1 µL of PE-conjugated anti-mouse CD31 antibody were added to a dilution of 1:500 
and the tube was incubated again for 30 min at 4°C. The cells were washed and 
resuspended in 500 µL PBS. 2 µL 7aad were added to a final concentration of 4 
µg/mL and the measurements were conducted (BD FACScan).  
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3. Cell culture experiments 
 
3.1. Initial mRNA expression screening 
 
For subsequent mRNA expression analysis, all cell lines (H460, H520, Calu-3, 
DMS53) were cultured under normal conditions on 10 cm petri dishes. Upon 
attainment of 70 % confluency, total RNA was isolated according to the procedure 
described later. The mRNA expression of VEGF-A, VEGF-C, VEGF-D, CSF-1 and 
ANGPTL4 was assessed.  
 
3.2. Investigation of ANGPTL4 expression under different conditions 
 
For the assessment of ANGPTL4 mRNA expression of cell lines (H460, H520, Calu-
3, DMS53) and metastatic cells (C3LuMet, C3LNMet, C3BrMet), isolated from organ 
tissue of tumor bearing mice, the cells were seeded onto 10 cm petri dishes and 
supplied with their respective media and incubated at 37°C and 5 % CO2. Once 70 % 
confluency was reached, different groups were established. Each cell type was 
incubated for 24 additional hours under normoxia or under hypoxia, either in medium 
with 10 % FBS, in medium deprived of FBS, in medium with 10 % FBS and with 
TGF-β1 added to a concentration of 100 pM, in medium without FBS and with TGF-
b1 added. In case of the FBS starved groups, starvation was applied 24 hours prior 
to TGF-β1 and/or hypoxia addition.  
Following the incubation, mRNA was isolated according to the procedure described 
later.  
For the assessment of ANGPTL4 protein secretion, the same cell lines were used 
and 3 x 104 cells were seeded onto two 92 well plates. The groups were established 
and incubation was conducted as for mRNA expression analysis. The experiment 
was performed twice in order to verify the result. 
Subsequently, the cell culture supernatant was used for the ELISA described later. 
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3.3. Migration 
 
Due to EMT, many a priori epithelial cells change into a mesenchymal-like phenotype 
during malignant transformation. This goes hand in hand with the acquirement of 
increased motility, allowing them to invade adjacent tissues and to actively enter or 
leave vessels, ultimately forming metastases. Eukaryotic cells have a typical 
diameter of 50-100 µm. If seeded onto a porous membrane with a pore diameter of 
only 8 µm, it is impossible for them to traverse it, unless they possess active 
migration capacity. For a defined number of cells seeded onto the membrane, the 
amount of cells which manage to get to the other side can be used for the relative 
quantification of migratory capacity between different cell types.  
DAPI (4',6-diamidino-2-phenylindole) is a fluorescent dye which strongly binds to 
DNA. It is excited by fluorescent light and can thus be used to identify migrated cells 
by staining their nucleus.  
 
Using cells from all cell lines, as well as isolated C3LuMet lung metastatic cells, a 
trans-well migration assay was performed. The wells of two 24-well plates were 
supplied with 500 µL medium containing 10 % FBS and a 8 µm permeable support 
(BD Falcon) was placed on each well. 2 x 105 cells of each cell line in 200 µL 
medium containing 1 % FBS were seeded onto the respective supports. Cells were 
incubated under normoxia or hypoxia for 24 hours (37°C, 5 % CO2). Following 
incubation, the supports were taken out and washed twice with 1 mL ice-cold PBS 
and 500 µL PBS were added. Cells remaining on the upper side of the membrane 
were carefully removed with cotton swabs and the membranes were cut out of the 
supports using a surgical blade. The membranes were then transferred upside down 
into clean wells containing 1 mL PBS. 1 mL of pre-chilled (-20°C) methanol was 
added to new wells and the membranes transferred from PBS to methanol. Fixation 
was performed for 2 min and the membranes were washed in ice-cold PBS. 1 µL of 
DAPI stock solution (1 mg/mL) was added to new wells containing 1 mL PBS to a 
final concentration of 1 µg/mL and the membranes were transferred to these wells. 
Staining was conducted for 10 minutes in the absence of light at room temperature. 
The membranes were washed twice in PBS, transferred to a glass slide and covered 
with a cover slip. They were observed through a microscope, 5 representative 
sectors were counted. 
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3.4. Tube formation 
 
Endothelial cells exhibit the ability to form three-dimensional capillary-like tubular 
structures when cultured on a gel of basement membrane extract, mimicking 
angiogenesis. This can be visualized and quantified relatively.  
 
In order to determine the possible influence of tumor cells on the tube formation 
ability of LECs, a matrigel tube formation assay was conducted in coculture. 
A 96-well tissue culture plate was supplied with 50 µL of growth-factor reduced 
matrigel (BD Biosciences). 1 x 104 tumor cells in 50 µL culture medium without FBS 
were added to the wells, as well as 1 x 104 DiI-labeled LEC cells in 50 µL culture 
medium without FBS. This was done for every tumor cell line (H460, H520, Calu-3 
and DMS53) and as a control, LEC cells alone were used. The plates were incubated 
at 37°C, 5 % CO2 and tube formation was monitored after 2, 8 and 24 hours. A high 
pressure mercury lamp was used to induce fluorescence in the labeled cells. Tubes 
were counted in 5 representative sectors, averaged and compared to the control. 
 
4. mRNA expression 
 
4.1. RNA-isolation 
 
TRIzol®Reagent is a ready-to-use reagent for the isolation of total RNA from cells and 
tissues. The reagent, which is a mono-phasic solution of phenol and guanidine 
isothiocyanate, maintains the integrity of the RNA, while disrupting cells and 
dissolving cell components. Addition of chloroform followed by centrifugation, 
separates the solution into an aqueous phase and an organic phase. RNA remains 
exclusively in the aqueous phase. After transfer of the aqueous phase, the RNA is 
recovered by precipitation with 2-propanol. 
 
Homogenization was the first step in RNA isolation. In the case of tumor tissue, 
approximately 10 mm³ of cryopreserved material were placed on dry ice and cut into 
small pieces using a clean razorblade. The pieces were transferred into a 1,5 mL 
eppendorf tube and 1 mL TRIzol Reagent (Invitrogen) was added. The tissue was 
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homogenized with a homogenizer (Heidolph Diax 900). 
For cells grown in culture, the culture medium was removed and 1mL TRIzol 
Reagent was directly added to the cells. The cell lysate was passed through a pipette 
several times and transferred into an 1,5 mL eppendorf tube. 
The next steps were identical for tissue and cultured cell RNA isolation. 
The homogenized samples were incubated for 5 minutes at room temperature in 
order to assure complete dissociation of nucleoprotein complexes. 200 µL of 
chloroform were added, the tubes were vortexed for 20 seconds and incubated at 
room temperature for another 3 minutes. The samples were centrifuged at 12000 x g 
for 15 minutes at 4°C. Following centrifugation, the upper aqueous phase was 
transferred into a new tube and the remaining organic phase was discarded. In order 
to precipitate the RNA, 500 µL -20°C isopropanol were added and the tubes were 
inverted several times to mix the solution. After 30 minutes of incubation as -20°C, 
the samples were centrifuged again at 12000 x g for 30 minutes at 4°C. The 
isopropanol was decanted off and 1 mL -20°C, 70 % ethanol was added to the pellet. 
The tubes were centrifuged again at 12000 x g for 8 min at 4°C and as much ethanol 
as possible was removed by pipetting, without disturbing the pellet. The remaining 
ethanol was allowed to evaporate for 30 minutes at room temperature and the RNA 
pellet was finally dissolved in 25 to 50 µL DEPC-treated water, depending on its size. 
The RNA was stored at -80°C. 
  
4.2. RNA quantification 
 
The RNA concentration can be determined by measuring the absorbance at 260 nm 
(A260). Quartz cuvettes are used in order to prevent absorbance by plastic or glass.  
Due to the partial overlapping of the absorbance of nucleic acids and proteins at 260 
nm (because of the aromatic amino acids tyrosine, phenylalanine and tryptophan) 
and the specific absorbance of proteins at 280 nm, the ratio A260/A280 can be used to 
determine the purity of the RNA. It should be between 1,8 and 2. 
 
The measurements were conducted as follows: 
The isolated RNA of tumor samples and cultured cells was incubated for 10 min at 
65°C on the heating block in order to separate RNA double strands. 1 µL of the 
solution was diluted in 999 µL ddH2O in an eppendorf tube and transferred to the 
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quartz cuvette. The absorption was measured at 260 and 280 nm on a 
spectrophotometer (Cary 50 Bio). The concentration of total RNA in the stock 
solution was calculated according to the following equation: 
C [µg/µL] = A260 x dilution factor x extinction coefficient 
 
4.3. Reverse transcription 
 
Complementary DNA (cDNA) is synthesized from a mature mRNA template in a 
reaction catalyzed by the enzyme reverse transcriptase. The reaction is a necessary 
step for subsequent quantitative real-time polymerase chain reaction (qRT-PCR), 
since DNA polymerase can only act on DNA templates. Because cDNA originates 
from processed mRNA, it lacks introns. 
 
Reverse transcription was performed as follows: 
2 µg of RNA were diluted to 10 µL with DEPC-treated water in an eppendorf tube. 1 
µL oligo-dT primer (1 µg/µL, Fermentas) was added and the mixture was incubated 
for 5 min at 70°C on the heating block. The tubes were transferred to ice, incubated 
for another 5 min and the condensed liquid was spun down. Reagents were added in 
the following amount and order: 
2,5 µL DEPC-treated water (Fermentas) 
4 µL RevertAidTM M-MuLV Reverse Transcriptase buffer (5x, Fermentas) 
1 µL dNTP mix (25 pmol, Fermentas) 
0,5 µL ribonuclease inhibitor (40 units, Fermentas) 
1 µL RevertAidTM M-MuLV Reverse transcriptase (200 units, Fermentas) 
For multiple samples, a master mix was made, multiplying the amounts by the 
number of samples plus 2. 
The mixture was incubated for 60 min at 42°C on the heating block and the cDNA 
was stored at -20°C. 
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4.4. Real-time PCR 
 
Real-time PCR uses the amplification of specific DNA fragments via polymerase 
chain reaction combined with a dye which preferentially binds to double stranded 
DNA (SYBR Green I) and exhibits fluorescence when bound only. A modified, 
thermo-stable Taq DNA polymerase (FastStart Taq Polymerase) is used. Specific 
primer pairs consisting of 18-21 bp DNA fragments are chosen to amplify the mRNA 
of interest. They should span intron-exon boundaries or their sequence should at 
least be located on two distant exons, in order to prevent the amplification of residual 
genomic DNA. Also, when working with a mixture of cells from two different 
organisms as it is the case with xenografted tumors, the primers must be species-
specific and their GC-content should be around 50 % to assure specific binding at 50 
to 65°C. The reaction itself comprises 45 PCR cycles and is performed in 20 µL 
capillaries which are placed in an RT-PCR cycler (LightCycler Instrument, Roche). 
Upon exponential amplification of the mRNA fragment, the amount of bound 
fluorescent dye increases accordingly. This can be detected by excitation at 488 nm 
and measurement of fluorescence at 522 nm. The number of cycles required to 
reach exponential amplification is inversely proportional to the original mRNA 
concentration of the sample. Primer specificity can be assessed after amplification by 
a melting curve analysis, which records the fluorescence while increasing the 
temperature. If the product is uniform, the synthesized DNA-duplexes melt and the 
fluorescence drops sharply at some point. The respective melting temperature is 
specific for each amplicon. In addition, the size of the fragment can be checked by 
agarose gel electrophoresis.  
Even though a defined amount of RNA was used initially for the reverse transcription, 
the efficiency of cDNA synthesis can vary strongly, due to differences in quality of the 
RNA. Therefore, the resulting data from a qRT-PCR is always compared to a 
housekeeping gene, which is assumed to be expressed to the same degree in every 
cell. In this case, the corresponding gene is beta-2-microglobulin (B2M), which is 
expressed ubiquitously in every nucleated cell as a component of major 
histocompatibility complex cIass I (MHC-I) molecules. This allows the relative mRNA 
quantification between samples. 
The used primer sequences are shown in the annex. 
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The qRT-PCR was conducted as follows: 
The cDNA samples were diluted 1:10 in DEPC treated water. 
For each sample, one 20 µL capillary was placed in precooled (4°C) centrifuge 
adapter and a master mix was prepared using components from the LightCycler 
FastStart Kit (Roche). 
 
Component and stock concentration Volume for one 
reaction 
Final 
concentration 
H2O, PCR grade  10,2 μL  
MgCL2 stock solution (25 mM)  1,3 μL 3 mM 
LightCycler FastStart DNA Master 
SYBR Green I  
1,5 μL 1x 
Forward primer (10 pmol) 0,5 μL 0.33 pmol 
Reverse primer (10 pmol) 0,5 μL 0.33 pmol 
Total volume 14 µL  
 
The amount of each reagent was multiplied by the number of samples plus 2. The 
LightCycler FastStart DNA Master SYBR Green I solution contains the dye, as well 
as the taq polymerase.  
14 µL of the master mix were pipetted into each capillary and 1 µL of diluted cDNA 
sample was added. The capillaries were sealed with a stopper and the liquid was 
spun down in a standard benchtop microcentrifuge (Heraeus Biofuge Pico). They 
were transferred into the LightCycler instrument and the PCR was conducted, 
comprising the following programs: 
First, a preincubation step was performed, heating the samples to 95°C for 10 min.  
The second program was repeated automatically 45 times and represents the actual 
PCR. It implied a fist segment, where primer dimers and double stranded DNA were 
separated. This was achieved by incubation at 95°C for 10 s. The second segment 
permitted primer annealing and had a specific temperature for every primer, ranging 
from 50 to 65 °C for 5 s. The last segment, the synthesis step, was performed at 
72°C, which is the optimal temperature for the taq polymerase. Its duration depended 
on the template length and was calculated by the formula: amplicon length [bp] / 25. 
After every synthesis cycle, the fluorescence intensity was measured. 
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Melting, the third program, was performed in order to establish a melting curve and 
thus identify the corresponding melting temperature for every amplicon. For this 
purpose, the samples were heated to 95°C in 0,1°C steps per second and the 
fluorescence was measured constantly. 
Data analysis was performed using LightCycler analysis software, which yielded a 
quantification curve, displaying the fluorescence values for each sample in relation to 
the cycle number and a melting curve, showing the derivative of the fluorescence 
value during the melting program in relation to temperature. 
 
4.5. Agarose gel electrophoresis 
 
Due to their phosphate backbone, nucleic acids are negatively charged. If they are 
added to an agarose gel matrix and an electric field is applied, they migrate towards 
the anode. Shorter molecules move faster than longer ones, due to the net-like 
structure of the gel which makes it possible to separate a mixture of nucleic acids 
according to their length. This method is called agarose gel electrophoresis. A DNA 
ladder which contains DNA fragments of a defined size can be run simultaneously to 
allow determination of the length of analyzed DNA. 
Ethidium bromide (EtBr) is an intercalating DNA dye, which is excited by ultraviolet 
light and emits an orange color. If it is added to the gel, it allows visualization of the 
DNA fragments.  
DNA samples must be mixed with a loading buffer, which contains bromphenol blue, 
which exhibits the same migration characteristics as a DNA fragment of 370 bp and 
allows monitoring the DNA movement during the experiment. In addition, the loading 
buffer contains sodium dodecyl sulfate (SDS) which eliminates DNA-protein 
interactions and the annealing of the ends of DNA molecules. Another component is 
glycerol, which permits the correct stacking of the sample inside the well. 
 
In addition to melting curve analysis, the amplification of human B2M was verified by 
agarose gel electrophoresis in a 1,5 % agarose gel. This was done for all primary 
organ isolates, where moderate or low cell proliferation could be observed, as well as 
for strongly proliferating, picked and subcultured cells from colonies of isolated organ 
cells. 
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Gel preparation and electrophoresis were conducted as follows: 
3 g agarose were added to 220 mL 1x TAE buffer in a clean 500 mL bottle. The 
solution was heated in a microwave, brought to boil and allowed to cool a little bit and 
brought to boil again. This was repeated until the agarose was fully dissolved. The 
solution was then allowed to cool to approximately 60 °C and 10 µL EtBr stock 
solution (10 mg/mL) were added and the gel to a final concentration of 0,5 µg/mL and 
the solution was poured into a 15 x 15 cm gel rack to obtain a gel of 1 cm thickness. 
A 30-well comb was inserted at one side and the gel was left to cool and solidify for 
about 30 min. The gel was removed from the rack and transferred to the 
electrophoresis apparatus, which was then filled with 1x TAE buffer to cover the gel. 
The capillaries from the qRT-PCR were removed from the PCR machine and put 
upside down into 1,5 mL eppendorf tubes. The tubes were put into a standard 
benchtop centrifuge and the liquid was transferred from the capillaries into the tubes 
by bringing the centrifuge to 3000 rpm and stopping it again. 
2,5 µL DNA loading dye (6x DNA Loading Dye & SDS Solution, Fermentas) were 
added to the 15 µL DNA samples and the samples were loaded into the wells of the 
gel, while sparing the 2 outer wells on each side. 10 µL of DNA ladder mix 
(GeneRuler DNA Ladder Mix 100-10000 bp, Fermentas) were added to one of the 
outer wells on both sides of the gel and ultra-low range DNA ladder (GeneRuler Ultra 
Low Range DNA Ladder 10-300 bp, Fermentas) was added to the other ones. 
The gel was run at 80V for 1,5 hours and photographs were taken in a long wave 
UV-box.  
 
5. Protein expression 
 
The ELISA (Enzyme Linked Immunosorbent Assay) technique is based on the 
antibody sandwich principle. First, a capture antibody, specific to the analyte of 
interest is bound to a microtiter plate and a sample or standard is added. If the 
sample is added, the analyte is retained on the plate by the first antibody and a 
second antibody is added, which binds another epitope but is also analyte-specific as 
well as biotinylated. Straptavidin, conjugated to the enzyme horse radish peroxidase 
(HRP), binds to the biotin of the second antibody. By addition of a substrate 
(tetramethylbenzidine and H2O2), the analyte can be quantified through a color 
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reaction.  
For the assessment of ANGPTL4 protein secretion, the same cell lines were used 
and the same culture conditions applied as for ANGPTL mRNA expression analysis. 
3 x 104 cells were seeded onto two 92 well plates. The experiment was performed 
twice in order to verify the result. An ELISA duo kit (R&D Systems) was used to 
assess ANGPTL4 expression. 
 
Plate preparation was conducted as follows: 
The capture antibody was reconstituted in 1 mL PBS to a stock concentration of 144 
µg/mL. 111,2 µL of capture antibody stock solution were diluted in 20 mL PBS to a 
working concentration of 0,8 µg/mL. 100 µL of this solution were pipetted into each 
well of two 96-well plates, the plates were sealed and incubated overnight at room 
temperature. The next day, the wells were emptied and washed with 400 µL wash 
buffer (0,05 % Tween 20 in PBS), which was discarded afterwards. This process was 
repeated twice for a total of three washes. The plates were blocked for one hour at 
room temperature by adding 300 µL of reagent diluent (1 % BSA in PBS, 0,2 µm 
filtered) to each well and the washing steps were repeated. 
 
Standards were generated as follows: 
Recombinant human ANGPTL4 protein was reconstituted in 0,5 mL reagent diluent, 
resulting in a stock concentration of 820 ng/mL. 78,04 µL of the protein stock solution 
were diluted in 721,96 µL reagent diluent to a final concentration of 80 ng/mL, which 
was used as the high standard. Four two-fold serial dilutions were made in eppendorf 
tubes, using 200 µL high standard solution every time and transferring 100 µL of this 
solution to a new eppendorf tube containing 100 µL reagent diluent. The resulting 
solutions were further diluted in the same way to a total of 7 concentrations (80, 40, 
20, 10, 5, 2,5 and 1,25 ng/mL).  
 
The assay was performed as follows: 
Of the four standard dilution series, two were pipetted onto each plate. 100 µL of 
sample or standard were added to the wells, the plates were sealed and incubated 
for 2 hours at room temperature. The aspiration/wash step was repeated as for plate 
preparation.  
Detection antibody was reconstituted with 1 mL reagent diluent to a stock 
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concentration of 72 µg/mL. Again, 111,2 µL of the stock solution were diluted in 20 
mL reagent diluent to a working concentration of 0,4 µg/mL.  
100 µL of detection antibody solution were added to each well, the plates were 
sealed and incubated for 2 hours at room temperature. The washing step was 
performed again. 
100 µL of Streptavidin-HRP solution were diluted in 20 mL reagent diluent and 100 
µL of the resulting solution were added to each well. The plates were incubated 
protected from light for 20 minutes at room temperature and washed. 100 µL 
substrate solution (tetramethylbenzidine/peroxide) were added to each well and the 
plate was again incubated, protected from light, for 20 minutes at room temperature. 
50 µL of 2 N H2SO4 were added to the wells and the optical density was measured 
using an ELISA reader at 450 nm. To correct for optical imperfections in the plates, 
the readings at 570 nm were subtracted.  A seven point standard curve was 
generated with the GraphPad Prism 5.0 software by the four parameter logistic 
curve-fit method and the ANGPTL4 concentration of samples was calculated by 
interpolation.  
 
6. Immunohistochemical staining 
 
Immunohistochemistry (IHC) is a method which allows the localization of cell-surface 
or intracellular proteins through the binding of specific antibodies. The method used 
involves a primary, unlabeled antibody which is antigen-specific and a secondary 
antibody, which is biotinylated and binds to the invariable fragment cristallizable 
region (Fc region) of the primary antibody. Streptavidin, conjugated to HRP can then 
bind the biotin of the secondary antibody and its location can be visualized by the 
addition of a substrate (diaminobenzidine and H2O2) through a color reaction. 
 
Von Willebrand Factor (vWF) is a glycoprotein, located on the surface of endothelial 
cells and plays a role in blood coagulation through the permission of thrombocyte-
binding. Even though it is also present on megakaryocytes and subendothelial 
connective tissue, it can be used as a marker for endothelial cells and thus serve to 
identify peri- and intratumoral blood vessels.  
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Ki-67 is a nuclear protein, associated with ribosomal RNA (rRNA) transcription. It is 
most abundant in proliferating cells and can serve as a marker for intra-tumoral cell 
division.  
 
Paraffin embedded tissue sections of extracted xenograft tumors were stained with 
rabbit anti mouse vWF (Dako) or mouse anti mouse Ki-67 (Dako) antibodies in order 
to assess vessel formation and tumor cell proliferation. 
 
Preparation and staining were conducted as follows: 
After tumor extraction, one half of the tumor was fixed in a 4 % formaldehyde solution 
for 1 week at 4°C. Following fixation, the samples were paraffin embedded and slices 
of 5 µm in thickness were made. The slices were transferred to glass slides and 
incubated in clean xylol for 15 min in order to deparaffinize them. The xylol was 
changed and the slices were again incubated for another 5 min. Hereafter, they were 
transferred to 96 % ethanol and incubated for 5 min. The ethanol was changed, the 
incubation was repeated and the slides were transferred to 70 % ethanol. After an 
incubation of 5 min, they were put into PBS. To assure the demasking of antigens, 
the slides were transferred to a tumbler and covered with citrate buffer (2 g tri-sodium 
citrate dihydrate in 1000 mL ddH2O, pH 6,5). They were heated in the microwave to 
95°C at 350 W for 20 min and allowed to cool for 10 min. Following a 5 min rinsing 
with tap water, the slides were washed in PBS and the samples were encircled using 
a delimiting pen (Dako). To avoid interference by any endogenous peroxidase 
activity, they were incubated in 6 % H2O2 for 20 min and rinsed again in PBS. 
Blocking solution (1 % BSA and 5 % horse serum in PBS) was added to the samples 
and they were incubated in a closed wet chamber for 10 minutes. The solution was 
dripped down. 10 µL primary vWF antibody solution were diluted in 2 mL PBS (1:200) 
and 27 µL primary Ki-67 antibody solution were diluted in 2 mL PBS (1:75). Either 
vWF or Ki-67 antibody solution was added to the slides, they were incubated in the 
wet chamber for 60 min at room temperature and washed 3 times with PBS. 20 µL of 
the secondary horse biotinylated anti-mouse/anti-rabbit antibody (Vector) stock 
solution were diluted in 4 mL PBS (1:200) and added to the slides, which were again 
incubated in the wet chamber for 60 min at room temperature. The slides were 
washed 3 times in PBS, 4 drops of Streptavidin-HRP solution were added (Dako) and 
they were incubated for 30 min in the wet chamber. They were rinsed again 3 times 
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in PBS and 5 drops of DAB/Peroxydase solution (Vector) were added. Incubation 
took place for 10 min and the slides were washed again in the same way.  
 
For counterstaining, Hematoxylin which colors basophilic structures, such as the 
nucleus and eosin which colors eosinophilic structures, such as the cytoplasm were 
used. The slides were washed for 5 min with ddH2O and incubated for 30 s with 
hematoxylin/eosin solution (Fluka). They were allowed to blue for 10 min under 
running tap water. 
 
In order to increase the stability of the stained slides, they were dehydrated by 
subsequent incubation for 5 min in 70 % ethanol, 96 % ethanol and, after drying, 
xylol. They were mounted by adding a drop of DPX (Fluka). 
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Results 
 
1. Initial mRNA expression screening 
 
1.1. Primer specificity 
 
Primer specificity was proven for all primers for human cDNA amplification, used in 
the subsequent experiments. These were huB2M, huVEGF-A, huVEGF-C, huVEGF-
D, huCSF-1, huANGPTL4, huTGF-β1 and huTGF-β2. In order to achieve this, qRT-
PCR was conducted with cDNA from mRNA isolated from human cells as well as 
mRNA isolated from murine muscle tissue. Melting curve analysis revealed that the 
primers permitted the amplification of human cDNA only, which is reflected by a 
readily discernable peak in the negative derivative of fluorescence intensity at the 
specific melting temperature (Figure 5). A decrease in fluorescence intensity reflects 
the melting of double stranded DNA at increasing temperatures. The melting 
temperature is proportional to the fragment length and thus specific. According to the 
manufacturer, a drop in fluorescence must be higher than 2 to discern the melting 
peak from background or artifact fluorescence. Amplification with huTGF-β1 primers 
also showed a distinct signal in the murine sample. Nevertheless, the lower melting 
temperature of 85°C and fluorescence intensity drop of 1 suggest a much shorter and 
less abundant fragment, possibly the result of primer-dimers.    
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Figure 5: Specificity of primers for human cDNA.  
Melting curves of amplified B2M, VEGF-A, VEGF-C, VEGF-D, CSF-1, ANGPTL4, TGF-β1 and TGF-β2 
cDNA fragments. The graphs represent the negative derivative of fluorescence intensity in relation to 
temperature. Only human cDNA samples (black lines) show a melting peak, whereas samples from 
murine tissue (grey lines) do not.   
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1.2. in vitro mRNA expression of angiogenic and lymphangiogenic factors  
 
RNA was isolated from all NSCLC (H460, H520 and Calu-3) and SCLC (DMS53) cell 
lines, reverse transcribed to cDNA and the expression of VEGF-A, VEGF-C, VEGF-D 
and CSF-1 was assessed by qRT-PCR. 
 
The results showed that VEGF-A was most abundantly expressed in Calu-3 cells, 
and present also in H460 cells. Calu-3 cells expressed VEGF-A approximately 5 
times stronger than H460 cells. Other cell lines show no expression at all, suggesting 
a possible high angiogenic activity in Calu-3 tumors, as well as possible higher 
metastatic potential (Figure 6A).  
Furthermore, VEGF-C expression was present in H460 and Calu-3 only. It was 
approximately 5 times higher in H460 than in Calu-3 cells, which could indicate a 
higher lymphangiogenic activity inside or in the periphery of H460 tumors, compared 
to other cell lines, suggesting possible higher metastases formation to the lymph 
nodes (Figure 6B).  
VEGF-D expression could be observed in all cell lines, most abundantly in Calu-3 
and H520 cells. For Calu-3, it was approximately 2,5 times as high as in H460 and 10 
times higher than in DMS53 cells. This correlates with a relatively high incidence of 
lymphatic endothelial cells in Calu-3 derived tumors, as shown later by FACS 
analysis as well as lymph node metastasis observed in vivo. 
For H520, VEGF-D expression was twice as high as in H460 cells and 8 times higher 
than in DMS53 cells. This is in accord with the high amount of tube formation by 
lymphatic endothelial cells in coculture with H520 cells shown later.  
Lastly, CSF-1 expression could only be observed in Calu-3 and H460 cells with Calu-
3 expressing approximately twice as much mRNA than H460, which could indicate a 
higher angiogenic and lymphangiogenic activity in tumors derived from these cells 
(Figure 6D). 
In summary, DMS53 showed the lowest expression of angiogenic and 
lymphangiogenic factors, whereas Calu-3 exhibits the highest expression for three of 
the four assessed factors. 
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Figure 6: in vitro mRNA expression of VEGF-A, VEGF-C, VEGF-D and CSF-1 in NSCLC and 
SCLC cell lines measured by qRT-PCR 
mRNA expression of human VEGF-A (A) with Calu-3 cells showing much higher expression than other 
cell lines; VEGF-C (B) with H460 cells showing the highest expression; VEGF-D (C) with Calu-3 and 
H520 showing the highest expression and CSF-1 (D) with Calu-3 showing the highest expression. 
Data are shown in arbitrary units (AU), normalized to the highest expression value for each assessed 
factor.  
2. Large cell and squamous cell bronchus carcinoma induce LEC 
tube formation 
A matrigel tube formation assay was conducted with all bronchus carcinoma cell lines 
in coculture with lymphatic endothelial cells (LECs) in order to assess a possible 
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influence on lymphangiogenic activity. LECs were previously DiI-labeled to discern 
them from tumor cells. Tube formation was checked every 4 hours for 24 hours and 
photomicrographs were taken (Figure 7). 
 
 
 
 
 
Figure 7: Tube formation by LECs on growth factor reduced matrigel. 
Photomicrographs (magnification: 100 x) of tube formation by DiI-labeled LECs in coculture with 
H460, H520, Calu-3 and DMS53 after 8 and 24 hours. After 8 hours, extensive tube formation 
compared to control (LECs only) can only be detected in H520 samples. After 24 hours, all samples 
show tube formation to a certain degree, the highest in H520 and H460 cocultured LECs. Arrows 
indicate tubes. To discern LECs from tumor cells, fluorescence images were taken, showing only the 
DiI-labeled LECs (FL) 
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Tube formation was quantified relative to the control (LECs only) by counting in 5 
representative sectors and averaging. LECs in coculture with H460 cells exhibited 
the fastest and strongest tube formation, 2,5 times higher than the control without 
tumor cells added at 24 hours incubation. LECs cultured with H520 cells also showed 
twice as much tube formation capacity as the control at 24 h. Calu-3 and DMS53 did 
not increase tube formation of LECs, with DMS53 even causing strongly decreased 
LEC capillary formation (Figure 8). 
The fact that H520 and H460 showed the highest tube formation induction in LECs is 
in accordance with the high VEGF-C expression of H460 and the high VEGF-D 
expression of H520, determined by qRT-PCR in vitro. 
Nevertheless, Calu-3 did not increase tube formation, despite its high VEGF-D 
expression. Hence, a universal correlation between VEGF-C or VEGF-D mRNA 
expression and LEC tube formation could not be established. 
 
  
 
 
 
 
 
 
 
Figure 8: Tube formation 
Relative quantification of tube formation 
capacity by LECs in coculture with H460, 
H520, Calu-3 and DMS53 after 2, 8 and 24 
hours. In vitro VEGF-C and VEGF-D mRNA 
expression of each cell line is indicated 
below. H520 and H460 show the strongest 
and fastest tube formation induction capacity. 
Data are expressed as mean ± SD in 
arbitrary units, normalized to the tube 
formation value of LECs only (n = 5). 
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3. Xenografts 
 
3.1. Large cell and squamous cell bronchus carcinoma show the fastest tumor 
growth 
 
The bronchus carcinoma cell lines used in the in vitro experiments (H460 large cell 
carcinoma, H520 squamous cell carcinoma, Calu-3 adenocarcinoma and DMS53 
small cell carcinoma) were injected into the flanks of athymic, nude mice (n = 8 for 
each cell line) in two different cell numbers (5 x 106 and 10 x 106, n = 4 for each cell 
number) in order to examine tumor growth. According to our termination criteria, 
animals were sacrificed as soon as the tumor size reached 2 cm3.  
Almost all injected cell lines exhibited 100 % tumor formation, except for DMS53 with 
only 2 out of 4 animals with 10 x 106 cells injected developing tumors. There were 
large discrepancies in growth rate and latency time between different cell lines.  
 
H460 large cell bronchus carcinoma cells showed the fastest growth, compared to 
the other cell lines, for both 5 x 106 and 10 x 106 cells injected. The 10 x 106 cell 
group reached a tumor size of 2 cm3 after 16 days and the animals were terminated 
accordingly at day 18 post injection (Figure 9A).  
H520 squamous cell bronchus carcinoma cells showed a far slower growth overall, 
with tumors attaining 2 cm3 for the 10 x 106 group after 32 days. For the 5 x 106 
group, tumor formation was almost unnoticeable during the first 30 days of the 
experiment and after this period, tumor size remained almost unchanged. The 
animals of the 5 x 106 and 10 x 106 groups were terminated at day 32 and 78 
respectively. The results indicate that 10 x 106 is an appropriate cell number for 
further experiments in order to assess the impact of applied therapies on tumor 
growth and metastasis (Figure 9B).  
Calu-3 bronchus adenocarcinoma cells showed growth rates similar to H520, with the 
10 x 106 group attaining 2 cm3 after 37 days and high growth latency for the 5 x 106 
group. Animals were killed at day 42 for the 10 x 106 group and day 49 for the 5 x 106 
group. It is important to note that the animals which had received 10 x 106 cells 
showed very heterogenic tumor growth. Nevertheless, 10 x 106 cells seem to be an 
appropriate cell number for the future investigation of metastases formation and 
therapeutic impact (Figure 9C). 
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DMS53 small cell bronchus carcinoma cells exhibited far less frequent tumor 
formation with two animals of the 10 x 106 cell group not developing tumors at all. 
The latency was higher than for every other cell line with stagnant tumor sizes up to 
day 40 post injection. In the case of the 5 x 106 cell group, tumor growth remained 
slow until termination at day 78. The 10 x 106 group however showed much faster 
growth after onset, with tumors reaching 2 cm3 after 59 days but owing to the long 
latency time and the fact that two animals did not develop any tumor at all, the cell 
concentration seems too low for future experiments. The animals were terminated at 
day 59 (Figure 9D). 
In summary, great discrepancies exist between the different bronchus carcinoma 
subtypes. H460 showed by far the fastest and DMS53 the slowest tumor growth rate. 
H520 and Calu-3 revealed considerable differences in tumor growth, depending on 
the cell number injected. The onset of tumor growth also varies greatly, with H460 
and H520 showing the earliest and Calu-3 and DMS53 the latest. All tumor cell lines 
developed spherical subcutaneous tumors comparable in shape, with no observable 
invasive process into the peritoneum (Figure 9E). 
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Figure 9: Establishment of lung cancer xenograft models in athymic, nude mice 
Tumor growth curves for H460 (A), H520 (B), Calu-3 (C), and DMS53 (D) (n = 4 for each cell line and 
number) and representative pictures of tumors (E). H460 shows the fastest tumor growth and DMS53 
the slowest. All tumors exhibit spherical morphology. Data are expressed as mean ± SD. 
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3.2. in vivo mRNA expression of angiogenic and lymphangiogenic factors 
 
RNA was isolated from all extracted tumor samples, reverse transcribed and qRT-
PCR performed for huVEGF-A, huVEGF-C, huVEGF-D and huCSF-1 (n = 8 for each 
cell line). 
 
All cell types showed VEGF-A mRNA expression with H520 and Calu-3 cells 
exhibiting the highest.  
In contrast to in vitro data, VEGF-A mRNA expression in H520 was the highest 
among all cell lines, 0,8 fold higher than in H460 and 0,6 fold higher than in DMS53 
cells. Accordingly, as shown later by immunohistochemical staining, tumors derived 
from H520 show the second highest overall vessel density. 
Expression in Calu-3 remained high as compared to the other cell lines with a 0,6 
fold increase compared to H460 and 0,3 fold compared to DMS53.  
H460, which had moderate expression in vitro, showed an increase in VEGF-A 
mRNA in vivo and DMS53 cells, which did not express VEGF-A in vitro, now had 
mRNA levels comparable to those of H460 cells (Figure 10A).  Physiological changes 
within the tumor, such as hypoxia may have induced VEGF-A expression (Figure 
10D).  
VEGF-C mRNA expression in tumor samples was present in all cell lines, except for 
DMS53. Again, H520, which did not express VEGF-C in vitro and Calu-3 showed the 
highest mRNA expression. VEGF-C expression was 0,5 fold higher in H520 as 
compared to Calu-3 and 1 fold higher as compared to H460 tumors. Calu-3 VEGF-C 
expression was 0,4 fold higher than in H460 tumors (Figure 10B).  
Accordingly, H520 cells exhibited the highest tube formation induction capacity in 
LECs in vitro, even though no lymphatic endothelial cells could be found inside the 
tumor tissue by FACS analysis, as shown later.  
VEGF-D mRNA expression was detected in all tumors, comparable to in vitro data. 
Calu-3 and H520 again showed the highest expression and H460 and DMS53 had 
comparable but lower expression, further underlining the possibility for 
lymphangiogenesis to play a role in Calu-3 and H520 tumor progression and 
increased metastases formation, observed in animals bearing these tumor types, as 
shown later (Figure 10C). 
CSF-1 mRNA could not be detected in any of the samples. 
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The variability was very high in all groups, indicating a high heterogeneity in gene 
expression even among tumors of the same type. 
 
 
 
 
 
 
 
 
 
 
Figure 10: in vivo mRNA expression of VEGF-A, VEGF-C, VEGF-D and CSF-1  
mRNA expression of huVEGF-A (A) huVEGF-C (B) and huVEGF-D (C) in tumor samples from H460, 
H520, Calu-3 or DMS53 bearing mice with H520 and Calu-3 having the highest levels in all cases. CSF-1 
expression in vivo is negative. Comparison of in vitro and in vivo expression (D) shows major changes in 
every cell line, except for Calu-3. Data are expressed as mean ± SD in arbitrary units (AU), normalized to 
the highest expression value of each assessed factor (n = 8 for each cell line). 
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3.3. Murine lymphatic endothelial cells are present within large cell bronchus 
carcinoma xenografts 
 
In order to determine the presence of lymphatic endothelial cells within the tumor, 
cells from unlabeled tumors were isolated and double-stained with antibodies against 
endothelium-specific CD31 (PE-labeled) and lymph-specific LYVE-1 (FITC-labeled) 
(n = 4 for each cell line). Dead cells were excluded by 7aad-staining. Following the 
staining procedure, the cells were subjected to flow cytometric analysis. Side scatter 
versus front scatter representation revealed a very heterogeneous cell mixture in all 
tumor isolates, containing cellular debris of very small size, as well as cellular 
aggregates of very large size, which were excluded by gating (Figure 12). 
Also, dead cells exhibiting high 7aad fluorescence, visualized in fluorescence 
channel 3 (fl3), were removed by gating (Figure 12). 
The FITC-fluorescence of LYVE-1 antibodies (fluorescence channel 1, fl1) was then 
plotted against the PE-fluorescence of CD31 antibodies (fluorescence channel 2, fl2) 
and single, as well as double positive cells could be identified and quantified by 
gating (Figure 12). Tumors derived from H460 showed 0,17 % percent CD31/LYVE-1 
double positive, intra-tumoral lymphatic endothelial cells, whereas H520 and Calu-3 
only showed 0,05 %. This suggests that H460 cells possibly promote 
lymphangiogenesis in vivo and is in accord with their high LEC tube formation 
induction capacity and their high VEGF-C mRNA expression in vitro (Figure 11). 
There were almost no lymphatic cells present in DMS53 derived tumors, which 
validated the mRNA expression and tube formation data. Even though H520 and 
Calu-3 showed high VEGF-D mRNA expression both in vitro and in vivo and high 
VEGF-C mRNA expression in vivo, tumors derived from these cells showed a much 
lower percentage of lymphatic endothelial cells (Figure 11). There may be a 
translational control mechanism involved or a higher density of extra-tumoral lymph 
vessels, which would not be included in this experiment. 
In summary, in vivo VEGF-C and VEGF-D mRNA expression did not correlate with 
LEC incidence within tumor tissue, except for large cell bronchus adenoma 
xenografts (Figure 11 B).  
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 Figure 11: Measurement of murine LECs in tumor tissue 
Percentage of CD31/LYVE-1 double positive cells in tumors of H460, H520, Calu-3 and DMS53 
cells (A). Data are expressed as mean ± SD (n = 4 for each cell line; * indicates p < 0,05; unpaired 
t-test) The table shows in vitro and in vivo VEGF-C and VEGF-D expression, as well as murine 
LEC incidence in tumor tissue (B). H460 is the only tumor subtype, which exhibited a significant 
number of murine LECs. 
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Figure 12: FACS analysis 
Representation of flow cytometric data. Front scatter/side scatter representation of H460 (A), H520 (D), Calu-
3 (G) and DMS53 (J) isolates. The gate excluding cellular debris and cell aggregates is shown in red. 7aad 
fluorescence (Fl 3) of H460 (B), H520 (E), Calu-3 (H) and DMS53 (K). Dead cells exhibiting high fluorescence 
(green) are excluded. FITC (Fl 1) and PE (Fl 2) fluorescence of gated, double stained H460 (C), H520 (F), 
Calu-3 (I) and DMS53 (L). Double positive murine LECs (blue) and their percentage are shown. H460 large 
cell carcinomas are the only tumors in which a significant number of LECs could be detected. 
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3.4. Large cell bronchus carcinoma xenografts show the highest proliferation 
rate and overall blood vessel density 
 
In order to determine the extent of cell proliferation and angiogenesis inside 
xenografted tumors, formalin fixed, paraffin-embedded tumor slices were 
immunohistochemically stained with antibodies against the proliferation-marker Ki67 
and the angiogenesis marker vWF. The relative extent of cell proliferation and 
angiogenesis was determined by the comparison of five representative microscopic 
fields of tumors from all cell lines.  
Ki67 staining revealed the highest proliferation rate for H460, compared to the other 
cell lines, which is in accord with its fast tumor growth (Figure 13A). vWF staining 
showed the highest vessel density for H460 as well, which is in contrast to its 
relatively low VEGF-A mRNA expression in vivo (Figure 13B). It has to be noted that 
this was only valid for peritumoral blood vessels, whereas intratumoral angiogenesis 
was low, compared to the other cell types (Figure 13C and D, Figure 14).  
H520 showed the second highest proliferation rate and vessel density, with abundant 
peritumoral as well as intratumoral vessel formation (Figure 13, Figure 14). This does 
reflect its high VEGF-A mRNA expression as well as its high metastatic activity in 
vivo, as shown later.  
Calu-3 showed lower proliferation rates than H460 and H520, mostly of glandular 
cells and the lowest vessel density among all cell types (Figure 13A and B). It did 
however show the highest number of intratumoral vessels. Furthermore, the 
observed blood vessels were larger in diameter compared to all other cell lines, 
which may be accounted for by the high VEGF-A mRNA expression of these tumor 
cells (Figure 13C and D, Figure 14). Also, Calu-3 exhibited the highest metastasis 
rate of all tumor types, as shown later.   
Lastly, DMS53 had very low proliferation rates, coinciding with its very high tumor 
growth latency (Figure 13A). The overall vessel density was comparable to Calu-3 
but there were slightly more peritumoral vessels present (Figure 13B and 14). 
Nevertheless, vessel diameter was much lower than for Calu-3. 
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Figure 13: Cell proliferation and vessel density inside xenograft tumors 
Relative quantification of cell proliferation (A), overall vessel density (B), peripheral vessel density (C) 
and central vessel density (D) of extracted tumors from all cell lines. H460 large cell carcinoma shows 
the highest proliferation and overall vessel density. This is attributable to the high number of peripheral 
vessels, whereas Calu-3 shows the highest density of central vessels. Data are expressed as mean ± 
SD in arbitrary units (AU), normalized to the highest value for each assessed feature (n = 5). 
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Figure 14: Ki67 and vWF stained tissue sections 
Representative pictures of Ki67 and vWF stained slices of extracted tumors from H460, H520, Calu-3 
and DMS53 cells. Proliferating, Ki67 positive cells (brown) are indicated by arrows (left). H460 shows 
by far the most proliferating cells, whereas DMS53 shows the least. Brown, vWF positive cells 
represent endothelial cells in peripheral tumor sections (center) and central tumor sections (right). 
H460 exhibits abundant peritumoral vessel (black arrows, PV) formation. Calu-3 and DMS53 show the 
highest number of central vessels (white arrows, CV) with higher diameter in the case of Calu-3. Note 
that Calu-3 tumors show glandular morphology only at the periphery. 
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4. Metastases 
 
4.1. Adenocarcinoma and squamous cell carcinoma exhibit frequent 
spontaneous metastasis in xenograft animals 
 
Among each tumor cell line and cell number group, two animals had received DiI-
labeled cells, which showed high fluorescence prior to injection (n = 2 for each cell 
concentration and cell line or n = 4 for each cell line). Lung, discernible lymph nodes, 
kidney and brain of these animals were extracted. Organ cells were isolated, cultured 
and monitored for fluorescence, which would indicate whether growing cells are of 
human provenance and thus represent tumor cells which had established distant, 
metastatic colonies in the respective organ. Presumably due to the nature of DiI as a 
lipophilic compound which gets diluted by 2 with every cell division, combined with 
the overall long tumor growth times, DiI fluorescence could not be detected in any of 
the samples, not even in the tumor itself.  
Therefore, another method had to be chosen to assess the human nature of growing 
cells. The isolates were allowed to grow for 4 weeks and subcultured if necessary as 
soon as they had reached 70 % confluency, in order to get an enrichment of 
proliferating cells. RNA was isolated, reverse transcribed to cDNA and specific qRT-
PCR was performed for human beta 2 microglobulin (huB2M). The results indicate 
that metastatic tumor cells were indeed present in various organs. For H460, human 
cells could be detected in the lung isolates of one animal which had received 10 x 106 
cells, which equals to 25 % of examined animals. For H520, they could be detected 
in the lung isolates of two animals, which had received 10 x 106 cells, representing 50 
% of examined animals. For Calu-3, cells of human nature could be detected in one 
lung isolate of an animal which had received 5 x 106 cells. Among the 10 x 106 
animals, human cells could be detected in the organs of both animals. One of them 
showed human B2M expression in all isolates (lung, lymph node, kidney and brain), 
while the other one showed expression in lung and lymph node isolates. Overall, this 
equals to as high as 75 % of all animals. In the case of DMS53, no cells of human 
provenance at all could be detected in any organ (Figure 15).  
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The correct amplification was checked by agarose gel electrophoresis, which showed 
that the huB2M fragment was either not present or of the expected length of 114 bp. 
(Figure 16) 
 
 
 
 
 
Figure 15: Metastasis in xenograft animals 
Overall percentage of the occurrence of metastases in H460, H520, Calu-3 and DMS53 tumor 
bearing mice, detected by specific qRT-PCR for huB2M (n = 4 for each cell line) (A). Calu-3 
adenocarcinoma exhibits the most frequent formation of metastases. Table indicating the site of 
metastasis for each cell line (B). Calu-3 is the only cell line which develops metastasis in all 
examined organs. 
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Figure 16: Agarose gel electrophoresis of huB2M PCR-Products 
Agarose gel electrophoresis of huB2M PCR-products from organ isolates showing cell growth. Lane 1: 
DNA Ladder Mix 100-10000 bp (Mix), 2: Ultra low range DNA ladder 10-300 bp (ULR), 3: H460 lung 
(Lu) isolate from 1 animal, 4-11: H520 brain (Br), kidney (Ki) and lung isolates from 3 animals, 12-25: 
Calu-3 lung isolates from 2 animals and lung, lymph node (LN), kidney and brain isolates from 1 
animal as well as cDNA from picked and subcultured cells from lung, lymph nodes and brain, 26-27: 
DMS53 lung and kidney isolated from 1 animal, 28: Positive control from cultured H460 cells, 29: Ultra 
low range DNA ladder 10-300 bp, 30: DNA ladder mix 100-10000 bp. Calu-3 adenocarcinoma shows 
the most frequent and widespread metastasis. 
 
If extensive cell division and colony formation could be observed, cells were picked, 
transferred to a new petri dish and further cultivated. This was the case for Calu-3 
lung, lymph node and brain isolates of 1 animal, which clearly showed morphological 
features of tumor cells, such as unlimited cell division, polymorphism, enlarged nuclei 
and granular chromatin. Photomicrographs were taken (Figure 17).  
 
 
 
 
Figure 17: Metastatic cells 
Photomicrographs of proliferating cells, picked from lung, lymph node and brain isolates of 
one Calu-3 bearing animal. High proliferation, as well as polymorphism and enlarged nuclei 
suggest a metastatic nature. 
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RNA was isolated from these cells as well and qRT-PCR for huB2M was conducted. 
The results showed that these cells really were of human origin and thus represented 
metastatic cells. They were dubbed C3LuMet for cells isolated from the lung, 
C3LNMet for cells isolated from the lymph node and C3BrMet for cells isolated from 
the brain (Figure 16). These cells were later used for the assessment of mRNA and 
protein expression of ANGPTL4 as well as migration.  
In summary, metastasis to the lungs was observed in 3 of 4 examined bronchus 
carcinoma cell lines, namely H460, H520 and Calu-3. Metastases formation in other 
organs was found in Calu-3 adenocarcinoma bearing mice only. Calu-3 also showed 
the highest overall metastasis rate. 
 
4.2. Metastatic adenocarcinoma cells show higher migratory capacity than the 
original cell line 
 
In order to investigate and to compare the migratory capacity of cell lines and 
isolated metastatic cells, a transwell migration assay was performed under normoxia 
and hypoxia with H460, H520, Calu-3, DMS53 and C3LuMet cells. After 24 h, the 
membranes were cut out, fixed, DAPI-stained, photomicrographs were taken and 
migrated cells in five representative regions were counted (Figure 18A) (n = 5 for 
each cell line). The results indicate that H460 cells have by far the highest migratory 
activity, whereas all other cell lines exhibit very low or almost no migration at all 
(Figure 18A and B). In addition, hypoxia increased cell migration in H460 cells by 129 
%, compared to normoxia. Interestingly, Metastatic cells isolated from the lungs of a 
Calu-3 tumor bearing mouse (C3LuMet) showed vastly increased migration 
compared to the original Calu-3 cell line (Figure 18C). Hypoxia increased this ability 
by another 100 % compared to normoxia. 
In summary, the migratory capacity of cells showing almost no migration under 
normoxia (H520, DMS53, Calu-3) was not significantly changed by hypoxia. In 
contrast, the migration of H460 and C3LuMet cells was strongly increased by the 
hypoxic environment.  
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Figure 18: Tumor cell migration 
Migration of tumor cells and isolated metastatic cells under normoxia and hypoxia. Representative 
photomicrographs (A), graphs quantifying the migratory capacity of H460, H520, Calu-3 and DMS53 
(B), or Calu-3 cells and isolated C3LuMet cells (C) H460 and C3LuMet showed the highest migratory 
capacity under normoxia. Hypoxia strongly increased migration for these two cell types. Data are 
expressed as mean ± SD (n = 5 for each cell line, *** indicates p < 0,001; unpaired t-test). 
 
4.3. Hypoxia strongly induces ANGPTL4 mRNA expression 
 
Tumor cell lines, isolated metastatic cells from Calu-3 tumor bearing mice, as well as 
cells isolated from the tumor itself (C3Tu) were cultured under serum starvation, 
hypoxia or both and ANGPTL4 mRNA expression was assessed by qRT-PCR. 
Serum starvation was chosen as a stress condition since it upregulates many cell 
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receptors, including TGF-βR, which has been shown to induce ANGPTL4. In 
addition, hypoxia is also known to increase ANGPTL4 expression139. 142.  
The results showed that starvation and hypoxia had an induction capacity for 
ANGPTL4 in all cells. However, induction by hypoxia was much stronger than by 
serum starvation. If both conditions were applied, mRNA expression was even higher 
than for hypoxia alone. Among the original cell lines, H460 showed the strongest 
expression under both hypoxia and starvation, 0,5 fold higher than DMS53, 0,9 fold 
higher than Calu-3 and 2 fold higher than H520 (Figure 19A). Induction of gene 
expression compared to control by exposition to starvation and hypoxia was also 
highest in H460 cells, with a 9 fold induction, compared to 7 for DMS53, 4 for H520 
and 1,5 for Calu-3.  
Calu-3 cells showed the highest expression a priori, 2 fold higher than H460, 2,9 fold 
higher than DMS53 and 3,7 fold higher than H520 (Figure 19A). 
This suggests that the high ANGPTL4 mRNA expression may play a role in 
metastases formation of H460 cells under hypoxia. However, the relatively high 
expression of ANGPTL4 by Calu-3 cells without any stimulation may also be of 
importance, possibly allowing quicker metastasis, without the need for extensive 
physiological stress. 
In the case of metastatic Calu-3 cells, ANGPTL4 mRNA expression under normoxia 
or serum starvation alone was lower than of the original cell line (Figure 19C). 
Nevertheless, hypoxia or both starvation and hypoxia greatly increased expression, 
compared to the cell line. If both conditions were applied, brain metastatic cells 
(C3BrMet) showed 3,8 fold, lymph node metastases (C3LNMet) 2,3 fold, lung 
metastatic cells (C3LuMet) 1,8 fold and tumor isolates (C3Tu) 1,4 fold higher 
ANGPTL4 mRNA expression than the original cell line. Expression induction by both 
starvation and hypoxia was much higher in metastatic cell lines, with a 14,6 fold 
induction in C3BrMet cells, 14,5 fold in C3LNMet cells, 11 fold in C3LuMet cells and 
10,5 fold in C3Tu cells compared to 1,5 fold in Calu-3 cells (Figure 19D).  
Summarizing, metastatic cells from Calu-3 bearing mice all showed much higher 
ANGPTL4 expression under hypoxia and under both hypoxia and starvation than the 
original cell line. The isolated tumor cells also show higher expression, which 
indicates a possible selection mechanism during tumor growth already. 
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Figure 19: mRNA expression of huANGPTL4 
mRNA expression of huANGPTL4 in H460, H520, Calu-3 and DMS53 tumor cell lines under serum 
starvation (grey bars), hypoxia (dark grey bars) or both (black bars) (A), corresponding fold expression 
induction compared to control (B). mRNA expression of isolated Calu-3 tumor (C3Tu) and metastatic 
(C3LuMet, C3LNMet and C3BrMet) cells under serum starvation, hypoxia or both (C), corresponding 
fold expression induction compared to control (D). Hypoxia and starvation induce huANGPTL4 mRNA 
expression. Isolated Calu-3 metastatic cells show the highest huANGPTL4 expression of all examined 
cells if both conditions are applied. mRNA data are expressed in arbitrary units (AU), normalized to the 
expression value of Calu-3 under normoxic conditions. One representative experiment out of two is 
shown. 
 
72 
 
4.4. Metastatic adenocarcinoma cells show the highest ANGPTL4 Protein 
expression 
 
An ELISA for human ANGPTL4 protein was performed with the same cells and under 
the same growth conditions as for mRNA expression analysis.  
The results showed that among cell lines, that the strongest protein expression 
occurs under hypoxia, as well as the highest relative induction. In contrast to mRNA 
expression however, the absolute protein secretion was lower under both starvation 
and hypoxia than under hypoxia alone (Figure 20A and B). Expression remained 
highest for H460 cells, even though it was similar to Calu-3 ANGPTL4 expression. 
Other cell lines showed very little expression or none at all.  
As compared to the low level of hypoxia-induced ANGPTL4 mRNA expression in 
Calu-3 cells, protein secretion was relatively high, possibly due to a post-
transcriptional control mechanism, which increases or stabilizes ANGPTL4 protein 
expression of Calu-3 cells. 
Absolute protein secretion of isolated metastatic cells was higher than of the original 
cell line, validating the results obtained by PCR. It was however highest under 
hypoxia and lower if both starvation and hypoxia were applied. Under hypoxia, all 
metastatic cells showed almost identical, high protein concentration of approximately 
25 ng/mL, whereas C3Tu showed 12,1 and the original cell line 15,5 ng/mL, 
compared to 3 ng/mL for the original cell line under normoxia (Figure 20C). This 
validates the mRNA data and proves that metastatic bronchus adenocarcinoma cells 
under hypoxia do indeed express more ANGPTL4 than the original cell line, 
increasing the possibility for ANGPTL4 to play a role in metastases formation. It 
should be noted that inducibility of ANGPTL4 was lower for metastatic cells than for 
Calu-3 cells (Figure 20D). This can be explained by the fact that metastatic cells 
already had high ANGPTL4 baseline protein levels under normal conditions, 
compared to the original cell line (Figure 20C). For example, the protein expression 
of 13,1 ng/mL by C3BrMet cells under normal conditions is almost as high as the 
protein expression of original Calu-3 cells under hypoxia (15,5 ng/mL). This suggests 
that ANGPTL4 could play a role in metastasis of bronchus adenocarcinoma, even 
without the need for physiological stress. 
Summarized, in contrast to serum starvation, exposure to hypoxia had a significant 
inducing effect on ANGPTL4 protein secretion. Isolated Calu-3 metastatic cells 
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showed much higher ANGPTL4 levels than the original cell line, even under normal 
growth conditions. This discrepancy was even more pronounced under hypoxia.  
 
 
Figure 20: huANGPTL4 protein expression 
Protein expression of huANGPTL4 from two independent experiments in tumor cell lines H460, H520, 
Calu-3 and DMS53 under serum starvation (grey bars), hypoxia (dark grey bars) or both (black bars) 
(A), corresponding fold expression induction compared to control (white bars) (B). Protein expression 
of isolated Calu-3 metastatic cells under serum starvation, hypoxia or both (C), corresponding fold 
expression induction as compared to control (D). Hypoxia strongly induced huANGPTL4 protein 
expression. Under hypoxia, isolated Calu-3 metastatic cells show the highest absolute and baseline 
expression of all examined cells. Data are expressed as mean ± SD. 
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4.5. TGF-β1 is a poor inducer for ANGPTL4 compared to hypoxia 
 
Since it has been shown that ANGPTL4 can be induced by TGF-β1, its effect on 
mRNA and protein expression of isolated metastatic cells was investigated. 
Metastatic cells were incubated under normoxia, serum starvation, hypoxia or both 
starvation and hypoxia in the presence or absence of human recombinant TGF-β1. 
huANGPTL4 mRNA and protein expression were assessed by qRT-PCR and ELISA 
respectively. mRNA results showed that TGF-β has the ability to further induce 
ANGPTL4 in the original cell line under hypoxia, increasing it 1,33 fold. If starvation 
and hypoxia were applied, the induction capacity sunk to 0,4 fold. C3Tu cells isolated 
from the tumor of Calu-3 bearing mice showed a similar result with 1,4 fold 
expression increase under hypoxia alone and 0,6 fold increase under both 
conditions. For metastatic cells, induction capacity under hypoxia was comparable to 
the original cell line. In the case of C3LuMet cells, with both conditions applied, TGF-
β caused a 1,5 fold increase in ANGPTL4 expression with the highest value among 
all samples. Interestingly, TGF-β was unable to increase ANGPTL4 expression in 
C3LNMet cells and C3BrMet cells if both conditions were true, suggesting that for 
these cells, induction by hypoxia was much more significant. Under normoxia or 
starvation alone, TGF-β hat no significant effect on ANGPTL4 mRNA expression, 
compared to hypoxia, which had a much higher impact. Overall, induction by hypoxia 
or both starvation and hypoxia is much more pronounced than by TGF-β, except for 
C3LuMet cells (Figure 21A). 
Protein data underlined the predominant effect of hypoxia on ANGPTL4 expression, 
compared to TGF-β addition. Among metastatic cells, if hypoxia or both starvation 
and hypoxia were applied, TGF-β further increased ANGPTL4 expression only 
between 0,04 (for C3Tu under hypoxia) and 0,4 fold (for C3BrMet under starvation 
and hypoxia). Nevertheless, TGF-β did increase ANGPTL4 protein expression 
strongly under normoxic conditions, between 2 (for C3BrMet) and 5 fold (for Calu-3) 
(Figure 21B). Starvation did not change inducibility by TGF-β, which was consistent 
with mRNA data. 
In summary, TGF-β did increase huANGPTL4 mRNA and protein expression in all 
isolated metastatic cells. However, the inducing effect of hypoxia was much more 
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pronounced.  
 
Figure 21: Effects of TGF-β1 on huANGPTL4 mRNA and protein expression 
Induction of huANGPTL4 by TGF-β1 in Calu-3, tumor isolates and metastatic (C3Tu, C3LuMet, 
C3LNMet and C3BrMet) cells under serum starvation (grey bars), hypoxia (dark grey bars) or both 
(black bars). mRNA data (A), protein data from two independent experiments (B). TGF-β1 induces 
ANGPTL4 in almost all cells. However, hypoxia had a much more pronounced effect on huANGPTL4 
mRNA and protein expression. mRNA data are expressed in arbitrary units (AU), normalized to the 
highest ANGPTL4 expression value. One representative experiment out of two is shown. Protein data 
are expressed as mean ± SD.  
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4.6. TGF-β1 and TGF-β2 mRNA expression does not correlate with ANGPTL4 
levels 
 
To assess whether high ANGPTL4-expression under hypoxia was a result of 
increased TGF-β1 or TGF-β2 expression by metastatic cells, their mRNA expression 
levels were measured by qRT-PCR. The results showed that neither TGF-β1, nor 
TGF-β2 mRNA expression was increased by hypoxia in any cell line (Figure 22A and 
B). Concerning TGF-β1, hypoxia even decreased expression to non-detectable 
levels. The relative upregulation of ANGPTL4 protein under normal conditions in 
metastatic cells as compared to Calu-3, shown by ELISA (Figure 20B) does not 
correlate with TGF-β expression either, since mRNA levels are lower in all metastatic 
cells than in the original cell line (except for TGF-β1 in C3LNMet) (Figure 22A).  
 
 
Figure 22: TGF-β1 and TGF-β2 mRNA expression 
TGF-β1 (A) and TGF-β2 (B) mRNA expression of Calu-3, isolated tumor (C3Tu) and metastatic cells 
(C3LuMet, C3LNMet, C3BrMet) under normoxia (Nx, white bars) and hypoxia (Hx, grey bars). TGF-β1 
and TGF-β2 mRNA levels of metastatic cells are lower or equivalent to Calu-3. Hypoxia did not 
increase TGF-β mRNA expression. mRNA data are expressed in arbitrary units (AU), normalized to 
the highest expression value of each assessed factor.  
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Discussion 
 
1. Angiogenesis and lymphangiogenesis 
 
Neoangiogenesis has been shown to be implicated in the process of metastasis for 
many cancers, including bronchus carcinoma. Not only can new blood vessels 
provide the necessary resources for further tumor growth, allowing the tumor to grow 
in size and subsequently permitting local invasion, but also do they represent a 
gateway into the whole body. The correlation between VEGF-A secretion, angiogenic 
activity in the tumor environment and metastatic activity has also been proven 
multiple times75, 78.  
The consequences of lymphangiogenesis in tumor progression are not as well 
understood as for blood vessels. There are indications that increased expression of 
the lymphangiogenic factors VEGF-C and VEGF-D correlates with higher incidence 
of metastasis to the lymph nodes as well as decreased survival in adenocarcinoma, 
as well as NSCLC patients90, 101. However, no functional intratumoral lymph vessels 
have been found so far102. Still, VEGF-C and VEGF-D expression definitely coincides 
with lymphangiogenesis in the adult organism for a number of other diseases100. 
The established xenograft model allowed the assessment of in vivo neoangiogenic 
and lymphangiogenic activity among all major subtypes of bronchus carcinoma. 
These phenotypic features could be compared to the expression of VEGF-A in the 
case of angiogenesis and VEGF-C and VEGF-D for lymphangiogenesis.  
 
For H460 large cell bronchus carcinoma cells, VEGF-A expression can be found in 
vivo, but lower than for the other cell lines. Still, a high number of peritumoral blood 
vessels can be detected and despite the short growth time, compared to the other 
tumors, 25 % of the animals show metastases. This is in accordance with clinical 
data, showing a high incidence of metastasis for this tumor type140. Given the low 
VEGF-A mRNA level, other angiogenic factors or stroma derived VEGF-A (e.g. by 
TAMs) may have contributed to increased angiogenesis in this case of large cell 
bronchus carcinoma82.  
H460 cells show higher migration than any other cell line, further underlining its 
metastatic potential. 
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Concerning lymphatics, H460 shows strong VEGF-C expression in vitro, compared to 
moderate levels of VEGF-C and VEGF-D in vivo. Accordingly, H460 shows high tube 
formation induction in LECs and it is the only cell line for which intratumoral LECs 
can be found by flow cytometry in relevant numbers. 
Since metastasis is an inefficient process, the high cell number injected and 
subsequent fast growth may have led to termination of H460 bearing animals prior to 
metastases formation. This is a drawback, limiting a comparison to the other cell 
lines. Further experiments, involving a lower injected cell number could be useful to 
investigate the role of angiogenesis and lymphangiogenesis in metastasis formation 
of H460 tumors. 
 
For H520 squamous cell bronchus carcinoma cells, no VEGF-A expression is 
detected in vitro. Nevertheless, high in vivo expression and corresponding vessel 
formation may have contibuted to the high metastasis rate of 50 %. Thus, 
neoangiogenesis, induced by tumor-secreted VEGF-A is likely to play a role in the 
metastatic progression of H520 tumors, validating past publications underlining the 
importance of VEGF-A mediated angiogenesis and subsequent metastasis141.  
The low migratory capacity of this cell line is contradictory to this but as for Calu-3, 
low initial migration rates do not necessarily predict a low metastatic potential. A 
clonal selection mechanism may subsequently increase the migration of H520 tumor 
cells. 
Despite the facts that H520 shows the highest tube formation induction capacity in 
vitro, the highest VEGF-C expression in vivo, as well as high VEGF-D expression 
both in vitro and in vivo, no LECs can be found by flow cytometry. This may be due to 
the fact that extratumoral lymphatics were not taken into account by the method. 
Nevertheless, lymphangiogenesis may still play a role in metastases formation of 
H520 tumors, given the evidence provided by this work.  
  
DMS53 shows no in vitro VEGF-A expression and in vivo expression is lower than for 
most of the other cell lines. Low in vivo expression is in accord with its low vessel 
density, vessel diameter, as well as the fact that no metastases could be identified in 
this small bronchus carcinoma xenograft model. Possibly, additional anti-angiogenic 
mechanisms are at work here. In this respect, a more thorough assessment of the 
expression of other angiogenic factors, such as angiopoietins would be reasonable.  
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Concerning the expression of lymphangiogenic factors, DMS53 exhibits low 
expression of VEGF-C and VEGF-D both in vivo and in vitro or even none at all. This 
is in conformity with its low ability to induce tube formation in LECs as well as the fact 
that no intratumoral lymphatic vessels could be identified.  
 
Calu-3 shows high VEGF-A expression both in vitro and in vivo, as well as a high 
density of intratumoral blood vessels and 75 % metastasis rate. This may indicate 
that in this case of lung adenocarcinoma, neoangiogenesis, induced by tumor-
secreted VEGF-A contributes to a high rate of intravasated tumor cells, leading to 
extensive metastasis formation. This is in concordance with previous publications, 
demonstrating the correlation between adenocarcinoma VEGF-A expression, 
vascularization and metastasis78. 
Calu-3 exhibits high VEGF-D expression both in vitro and in vivo, as well as high 
VEGF-C expression in vivo. Accordingly, it exhibits metastasis to the lymphnodes in 
this xenograft model, validating past publications90. Still, Calu-3 neither shows the 
ability to induce LEC tube formation, nor can murine LECs be found inside the tumor 
tissue. Again, peritumoral lymphatics could play a role in this respect, adding to the 
effect of angiogenesis on metastasis formation. Further investigation, comprising the 
assessment of peritumoral lymphangiogenesis could elucidate these findings. 
The high migration rate of isolated metastatic cells compared to the original cell line 
provides evidence that clonal selection may have taken place and that a 
subpopulation of Calu-3 cells may have acquired increased migratory capacity in the 
course of tumor progression. 
 
In summary, VEGF-A mRNA expression does correlate with vessel formation and 
metastasis rate in the investigated squamous cell bronchus carcinoma and 
adenocarcinoma tumors but not the large cell bronchus carcinoma, which shows only 
moderate levels. CSF-1 is undetectable in vivo in all cases and thus does not seem 
to contribute to VEGF-A expression, even though adenocarcinoma cells exhibit high 
in vitro levels. Our further investigations will focus on the influence of stromal VEGF-
A and its impact on tumor angiogenesis. VEGF-C and VEGF-D mRNA expression 
does not generally reflect the degree of LEC tube formation induction in vitro and a 
significant number of invading murine LECs could only be found in large cell 
bronchus carcinoma xenografts. We will assess the role of peritumoral lymphatics 
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thoroughly in the future. Metastasis does occur in all three examined NSCLC 
subtypes, with the highest incidence in adenocarcinoma bearing animals. The 
isolated metastatic adenocarcinoma cells will be extensively studied by our 
laboratory, concerning the mRNA and protein expression of multiple angiogenic and 
lymphangiogenic factors, compared to the original cell line. This may provide further 
insight into the molecular mechanisms of metastasis in bronchus adenocarcinoma. 
Future xenograft experiments with these cells will subsequently enable us to evaluate 
the effectiveness of anti-metastatic therapies.   
 
2. ANGPTL4 
 
The role of ANGPTL4 in cancer progression is poorly studied, possibly because it is 
outshined by the impact of ANGPTL4 on triglyceride metabolism, which also has 
many implications concerning health. Nevertheless, ANGPTL4 has been shown to be 
involved in endothelial cell-cell adhesion as well as in tumor metastasis, although 
reports concerning the latter are ambiguous138, 139.  
Also, recent publications suggest its upregulation by fasting, hypoxia as well as TGF-
β139. The upregulation by hypoxia is attributed to the activation of HIF-1α. 
 
According to this work, hypoxia increases ANGPTL4 mRNA as well as protein 
expression in general, validating past publications138, 139. Serum starvation shows an 
inhibitory effect on ANGPTL4 expression. Furthermore, even though the combination 
of starvation and hypoxia leads to increased ANGPTL4 mRNA expression levels, 
compared to hypoxia alone, this is not reflected by protein data. Still, since tumor 
environments definitely show hypoxic regions, it can be hypothesized that ANGPTL4 
is upregulated under in vivo conditions in all bronchus carcinoma types investigated 
here, although to a different degree. 
The influence of TGF-β addition on ANGPTL4 expression is detectable but minor, 
compared to hypoxia. Also, hypoxia does not increase TGF-β mRNA expression in 
tumor cells. Serum starvation does not significantly increase ANGPTL4 protein 
expression in response to TGF-β addition in this particular case, although past 
publications infer that TGF-β receptor expression is upregulated by this condition142. 
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Thus a different regulatory mechanism, such as the HIF-1α pathway, may be driving 
ANGPTL4 expression in bronchus carcinoma progression. 
   
H460 shows the highest expression level of ANGPTL4 protein and mRNA under 
hypoxia, compared to the other primary cell lines. Despite the fact that no metastatic 
cells could be isolated, metastasis did occur, as shown by qRT-PCR. Thus, the high 
ANGPTL4 expression may contribute to the early formation of metastases by H460 
tumor cells. Again, further experiments, decreasing the injected cell dose would most 
likely be helpful to further investigate this effect. 
 
According to expression data in the cell line, the role of ANGPTL4 in the formation of 
metastases by H520 does not seem to be as important as for other bronchus 
carcinoma subtypes, since no observable protein expression occurred and mRNA 
levels were lower than for the other cell lines. Nevertheless, this may be due to the 
harsh culture conditions and may not reflect the actual in vivo environment. 
Furthermore, no metastatic cells could be isolated from extracted organs in this case 
either, leaving the possibility that H520 metastases may still express higher amounts 
of ANGPTL4. Further experiments are necessary, involving stably (e.g. GFP) labeled 
tumor cells, which can be identified and isolated more easily from organ tissue.  
 
For DMS53, as for H520, small amounts of ANGPTL4 protein are secreted under 
hypoxia, while none at all are detectable under normal growth conditions. mRNA 
levels do however rise. Again, this suggests a less pronounced importance of 
ANGPTL4 in the formation of metastases in small cell bronchus carcinoma but since 
expression induction is measurable on the mRNA level, the growth conditions are to 
be reevaluated. Nevertheless, DMS53 does not form any metastases at all, which 
may be partly attributable to its low ANGPTL4 expression. 
 
The original Calu-3 cell line shows high ANGPTL4 protein expression under hypoxia, 
compared to the other cell lines and in the case of isolated metastatic cells, this effect 
is even more pronounced. Also, all metastatic cells show strongly increased protein 
expression under normal growth conditions compared to the original cell line. 
Together these data suggest that a selection mechanism during tumor progression 
has favored the survival of ANGPTL4 protein expressing cells, even without the 
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influence of hypoxia. It can be suspected that a mutation may have subverted 
existing regulatory mechanisms, leading to constitutively expressed ANGPTL4 
protein. Since mRNA levels in metastatic cells under normal growth conditions are 
not increased, this control mechanism may be located at the post-transcriptional 
level. Further experiments, involving the inhibition of ANGPTL4 expression and its 
effect on metastasis, as well as ANGPTL4 overexpression in metastatic cells could 
provide more evidence for the importance of this protein in the formation of 
metastases. Still, it is probable that ANGPTL4 may enhance the metastatic potential 
of human lung adenocarcinoma cells, establishing the possibility of future therapeutic 
options. 
 
In summary, except for the squamous cell bronchus carcinoma, ANGPTL4 
expression does correlate with metastases formation in all examined NSCLC and 
SCLC subtypes. This correlation is especially pronounced in the case of 
adenocarcinoma xenografts for which metastatic cells exhibit significantly stronger 
ANGPTL4 protein expression than the original cell line. The established murine 
model will allow us to further investigate the effect of ANGPTL4 on bronchus 
carcinoma progression in order to elucidate the possible causal relation between 
increased protein secretion and metastasis. This relation may include the previously 
studied endothelium disruptive effect of ANGPTL4, which may facilitate intra- or 
extravasation of motile tumor cells138, 139.    
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Appendix 
Media, Buffers and Solutions 
Cell culture media  
Components [mg/L] RPMI MEM Waymouth's 
Inorganic Salts         
Calcium Nitrate • 4H2O  100     
Calcium Chloride anhydrous    200 90,6 
Potassium Chloride  400 400 150 
Magnesium Chloride     112,56 
Magnesium Sulphate  48,8 97,7 97,67 
Sodium Chloride  6000 6800 6000 
Di-Sodium Hydrogen Phosphate (anh.)  800 140 300 
Sodium Hydrogen Carbonate  2000 2200 2240 
Amino Acids        
L-Alanyl-L-Glutamine 445,9 434   
L-Arginine • HCl  241,86 126 75 
L-Asparagine • H2O  50     
L-Aspartic Acid  20   60 
Cysteine HCl • H2O      100,29 
L-Cystine  50 24 20 
L-Glutamic Acid  20   150 
L-Glutamine 300 292 350 
Glycine  10   50 
L-Histidine Base  15     
L-Histidine • HCl • H2O    42 164,1 
L-Hydroxyproline  20     
L-Isoleucine  50 52 25 
L-Leucine  50 52 50 
L-Lysine • HCl  40 72,5 240 
L-Methionine  15 15 50 
L-Phenylalanine  15 32 50 
L-Proline  20   50 
L-Serine  30     
L-Threonine  20 48 75 
L-Tryptophan  5 10 40 
L-Tyrosine  20   57,66 
L-Valine  20 46 65 
Vitamins        
P-Aminobenzoic Acid  1     
Ascorbic Acid     17,5 
D(+)-Biotin  0,2   0,02 
D-Calcium Pantothenate  0,25 1 1 
Cholin Chloride  3 1 250 
Folic Acid  1 1 0,4 
Myo-Inositol  35 2 1 
Nicotinamide  1 1 1 
Pyridoxine • HCl  1 1 1 
Riboflavin  0,2 0,1 1 
Thiamine • HCl  1 1 10 
Vitamin B12  0,005   0,2 
Other Components        
D-Glucose anhydrous  2000 1000 5000 
Glutathione (red.)  1   15 
Hypoxanthine     29 
Phenol Red 5 11 10,2 
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Buffers and Solutions 
 
 
Name Formulation 
PBS 
KCl (0,2 g/L), KH2PO4 (0,2 g/L), NaCl (8 g/L), 
Na2HPO4anh. (1,15 g/L) 
Erythrocyte lysis buffer NH4Cl (8,26 g/L), KHCO3 (1 g/L), EDTA (0,037 g/L) 
 
RevertAid M-MuLV Reverse Transcriptase 
Buffer (5x) 
Tris-HCl (250 mM), KCl (250 mM), MgCl2 (20mM), DTT 
(50 mM), pH 8,3 
 
TAE buffer (1x) Tris-acetate (40 mM), EDTA (0,1 mM) 
Citrate buffer Tri-sodium citrate dihydrate (10 mM), pH 6,5 
DAB solution 
Buffer stock solution (2 drops), DAB stock solution (4 
drops), 30 % H2O2 (120 µL) ad 5 mL with ddH2O 
 
 
Primer Sequences 
 
 
Primer Accession nr. Forward Primer (5'-3') Reverse Primer (5'-3') 
Product 
length 
(nt) 
huβ2M NM_004048 GATGAGTATGCCTGCCGTGTG CAATCCAAATGCGGCATCT 114 
huVEGF-A all isoforms AGAAGGAGGAGGGCAGAATC GCATTCACATTTGTTGTGCTG 300 
huVEGF-C X94216 CCCCAAACCAGTAACAATC CACAGGCACATTTTCCAG 497 
huVEGF-D D89630 GCGGCAACTTTCTATGAC GGCAACTTTAACAGGCAC 285 
huCSF-1 M37435 GCTGTTGTTGGTCTGTCTC CATGCTCTTCATAATCCTTG 335 
huANGPTL4 NM_139314.1 CACAGCCTGCAGACACAACTC GGAGGCCAAACTGGCTTTGC 133 
huTGF-β1 NM_000660.4 TGGCGATACCTCAGCAAC CTCGTGGATCCACTTCCAG 405 
huTGF-β2 NM_001135599.1 ATCCCGCCCACTTTCTACAGAC CATCCAAAGCACGCTTCTTCCG 565 
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Abbreviations 
 
 
°C Degree celsius 
µg Microgram 
µL Microliter 
µm Micrometer 
µM Micromolar 
7aad 7-Amino-Actinomycin D 
A Absorption 
ANG Angiopoietin 
ANGPTL4 Angiopoietin like-4 
AU Arbitrary unit 
B2M Beta-2-microglobulin 
bFGF Basic fibroblast growth factor 
bp Base pairs 
cDNA Complementary DNA 
CSF-1 Colony stimulating factor-1 
CSF-1R CSF-1 receptor 
C-terminal Carboxy-terminal 
DAB Diaminobenzidine 
DAPI 4',6-diamidino-2-phenylindole 
ddH2O Double distilled water 
DiI 
1,1 '-dioctadecyl-3,3,3 ',3 '-
tetramethylindocarbocyanine iodide 
DNA Desoxyribonucleic acid 
dNTP Desoxyribonucleotidetriphosphate 
dpi Days post injection 
DSS Distal splice site 
EC Endothelial cell 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
ELISA Enzyme-linked immunosorbent assay 
EMT Epithelial to mesenchymal transition 
EtBr Ethidium bromide 
FBS Fetal bovine serum 
Fc region Fragment cristallizable region 
FITC Fluorescein isothiocyanate 
G Gravitational constant 
h Hour 
HIF-1α Hypoxia inducible factor-1α 
HRP Horse raddish peroxydase 
IGF-1 Insulin-like growth factor-1 
IHC Immunohistochemistry 
LEC Lymphatic endothelial cell 
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LYVE-1 Lymphatic vessel hyaluronan receptor-1 
MHC-1 Major histocompatibility complex-1 
min Minute 
mL Milliliter 
mm Millimeter 
mM Millimolar 
mRNA Messenger RNA 
NEAA Non-essential amino acids 
ng Nanogram 
nm Nanometer 
NSCLC Non-small cell lung cancer 
N-terminal Amino-terminal 
PBS Phosphate buffered saline 
PC Proprotein convertase 
PCR Polymerase chain reaction 
PDGF Platelet-derived growth factor 
PE Phycoerythrin 
PECAM-1 Platelet endothelial cell adhesion molecule-1 
PlGF Placental growth factor 
PSS Proximal splice site 
qRT-PCR Quantitative real-time PCR 
RNA Ribonucleic acid 
rRNA Ribosomal RNA 
s Second 
SCLC Small cell lung cancer 
SDS Sodium dodecyl sulfate 
TAE Tris, acetic acid, EDTA 
TAM Tumor associated macrophage 
Taq Thermus aquaticus 
TGF-β Transforming growth factor-beta 
TNF-α Tumor necrosis factor-α 
VEGF Vascular endothelial growth factor 
VEGF-R VEGF receptor 
vWF Van Willebrand factor 
W Watt 
 
 
 
 
 
 
 
 
100 
 
Abstract 
Neoangiogenesis is the formation of new blood vessels in the adult organism and a 
prerequisite for the establishment of distant colonies by many cancers, including 
bronchus carcinoma. Lymphangiogenesis represents the formation of new lymphatic 
vessels and has recently been implicated in the seeding of metastases. 
The aim of this thesis was to develop murine xenograft models for representative cell 
lines of all major bronchus carcinoma subtypes. Using H460 large bronchus 
carcinoma cells, H520 squamous cell bronchus carcinoma cells, Calu-3 
adenocarcinoma cells and DMS53 small cell bronchus carcinoma cells, differences in 
tumor growth, neoangiogenesis, lymphangiogenesis, metastasis and the presence of 
invading lymphatic endothelial cells (LECs) were evaluated. In addition, the question 
was addressed whether these phenotypic differences correlate with mRNA or protein 
expression of candidate angiogenic and lymphangiogenic factors, such as members 
of the vascular endothelial growth factor (VEGF) family, colony stimulating factor-1 
and angiopoietin-related molecule angiopoietin like-4 (ANGPTL4). 
Neoangiogenesis was observed in all tumor samples examined. Overall vessel 
density was highest in H460 derived tumors, whereas Calu-3 xenografts showed the 
highest number of large intra-tumoral vessels. VEGF-A mRNA expression in vivo 
correlated with blood vessel development in most tumor types, except for H460, 
where only moderate expression was observed. Lymphatic vessel formation was not 
observed in any of the tumors despite VEGF-C and VEGF-D mRNA expression. With 
the exception of DMS53, all tumors showed metastasis formation and a correlation 
with intra-tumoral vascularization was established. Calu-3 xenografts exhibited the 
highest frequency of metastasis and metastatic cells could be isolated from the 
organs of Calu-3 bearing animals. Calu-3 cells also showed high ANGPTL4 protein 
expression in vitro and hypoxia vastly increased protein secretion from this cell line. 
Importantly, isolated metastatic Calu-3 cells exhibited much higher ANGPTL4 protein 
levels than the original cell line under normoxia, as well as hypoxia, indicating a 
possible role of ANGPTL4 in the metastatic spread of bronchus adenocarcinoma. 
The results provided by this thesis underline the importance of VEGF-A induced 
neoangiogenesis in the metastatic spread of bronchus carcinoma, while the role of 
VEGF-C and VEGF-D remains unclear. Furthermore, they indicate a possible 
influence of ANGPTL4 in this context. 
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Zusammenfassung 
Neoangiogenese, die Ausbildung neuer Blutgefäße im adulten Organismus, ist eine 
notwendige Voraussetzung für die Metastasenbildung vieler Krebsarten, so auch des 
Bronchuskarzinoms. Lymphangiogenese, die Ausbildung neuer Lymphgefäße, ist 
erst seit kurzem Gegenstand der Forschung, scheint aber eine ähnliche Rolle in 
Bezug auf die Metastasenbildung zu spielen. 
Ziel dieser Diplomarbeit war die Etablierung muriner Xenograft-Modelle mit 
repräsentativen Zelllinien aller Bronchuskarzinom-Hauptsubtypen. Zellen des 
großzelligen Bronchuskarzinoms (H460), des Plattenepithelkarzinoms (H520), des 
Adenokarzinoms (Calu-3), sowie des kleinzelligen Bronchuskarzinoms (DMS53) 
wurden verwendet um Unterschiede in Wachstum, Neoangiogenese, 
Lymphangiogenese, Metastasierung sowie die Anwesenheit von murinen 
lymphatischen Endothelzellen (LECs) zu untersuchen. Zudem wurde der Frage auf 
den Grund gegangen, ob diese phänotypischen Unterschiede mit der mRNA bzw. 
Protein-Expression bekannter angiogener und lymphangiogener Faktoren korellieren, 
wie beispielsweise den Mitgliedern der vascular endothelial growth factor Familie 
(VEGF), dem colony stimulating factor-1, sowie dem vor kurzem entdeckten Molekül 
angiopoietin like-4 (ANGPTL4).  
Neoangiogenese konnte in allen untersuchten Tumorproben nachgewiesen werden. 
Tumore aus H460 Zellen zeigten die höchste insgesamte Blutgefäßdichte, obwohl 
die intratumorale Gefäßdichte bei Calu-3 höher war. Die in vivo VEGF-A mRNA 
Expression korellierte mit der Blufgefäßdichte in den meisten Tumorsubtypen, jedoch 
nicht beim großzelligen Bronchuskarzinom. Die Ausbildung neuer Lymphgefäße 
konnte in keiner der Tumorproben nachgewiesen werden, trotz vorhandener VEGF-C 
und VEGF-D mRNA Expression. Alle Tumorsubtypen zeigten Metastasenbildung, mit 
Ausnahme von DMS53. Eine Zusammenhang mit der intra-tumoralen 
Vaskularisierung konnte festgestellt werden. Calu-3 zeigte die höchste 
Metastasierungsrate und metastatische Zellen konnten aus den Organen Calu-3 
tragender Tiere isoliert werden. Calu-3 Zellen zeigten hohe ANGPTL4 
Proteinexpression in vitro, welche durch Hypoxie stark gesteigert wurde. Die 
isolierten, metastatischen Calu-3 Zellen zeigten noch höhere ANGPTL4 
Proteinwerte, als die ursprüngliche Zelllinie, sowohl unter Normoxie, wie auch unter 
Hypoxie. Dies weist auf eine mögliche Rolle von ANGPTL4 bei der 
Metastasenbildung des Adenokarzinoms hin. 
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Die Ergebnisse dieser Diplomarbeit unterstreichen die Wichtigkeit von VEGF-A 
induzierter Neoangiogenese bei der metastatischen Verbreitung des 
Bronchuskarzinoms, wohingegen die die Rolle von VEGF-C und VEGF-D unklar 
bleibt. Des weiteren deuten sie auf einen möglichen Einfluss des ANGPTL4-Proteins 
hin. 
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